

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
22 November 2001 (22.11.2001)

PCT

(10) International Publication Number
WO 01/88148 A2(51) International Patent Classification⁷: C12N 15/54,
9/12, C12Q 1/68, C07K 16/40, A01K 67/027, A61K
38/00, G01N 33/50

(21) International Application Number: PCT/US01/15776

(22) International Filing Date: 17 May 2001 (17.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/205,228 17 May 2000 (17.05.2000) US
09/734,032 12 December 2000 (12.12.2000) US
09/816,094 26 March 2001 (26.03.2001) US(71) Applicant: APPLERA CORPORATION [US/US];
Robert A. Millman, Assistant Secretary, 761 Main Avenue,
Norwalk, CT 06859 (US).(72) Inventors: WEI, Ming-Hui; Celera, 45 West
Gude Drive, Rockville, MD 20850 (US). CHAN-
DRAMOULISWARA, Ishwar; Celera, 45 West Gude
Drive, Rockville, MD 20850 (US). YE, Jane; Cel-
era, 45 West Gude Drive, Rockville, MD 20850 (US).
KETCHUM, Karen, A.; c/o Celera, 45 West Gude
Drive, Rockville, MD 20850 (US). DI FRANCESCO,
Valentina; Celera, 45 West Gude Drive, Rockville, MD
20850 (US). BEASLEY, Ellen, M.; Celera, 45 West Gude
Drive, Rockville, MD 20850 (US).(74) Agent: MILLMAN, Robert, A.; Celera Genomics Corp.,
45 West Gude Drive C2-4, Rockville, MD 20850 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,

[Continued on next page]

(54) Title: ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN KINASE PRO-
TEINS, AND USES THEREOF(57) Abstract: The present invention provides amino acid sequences of pep-
tides that are encoded by genes within the human genome, the kinase peptides
of the present invention. The present invention specifically provides isolated
peptide and nucleic acid molecules, methods of identifying orthologs and par-
alogs of the kinase peptides, and methods of identifying modulators of the ki-
nase peptides.

1 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
51 AGGGAGGAGT GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
101 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
151 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
201 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
251 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
301 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
351 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
401 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
451 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
501 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
551 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
601 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
651 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
701 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
751 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
801 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
851 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
901 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
951 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1001 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1051 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1101 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1151 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1201 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1251 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1301 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1351 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1401 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1451 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1501 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1551 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1601 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1651 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1701 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1751 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1801 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1851 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1901 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
1951 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
2001 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
2051 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
2101 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
2151 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
2201 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
2251 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
2301 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
2351 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
2401 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
2451 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
2501 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG
2551 GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG GGGAGGAGG (SEQ ID NO:1)

SEQUENCE:
5'UTR: 1-774
Start Codon: 115
Stop Codon: 2046
3'UTR: 2049

SOURCE: HUMAN

Tissue: HUMAN

gi|111111111|gb|U00000.1| (AR010154) serine/threonine protein kinase 2... 614 0-0
gi|174278881|gb|U00000.1| (AR010154) serine/threonine-specific kinase 2... 253 30-48
gi|174278881|gb|U00000.1| (AR010154) serine/threonine-specific kinase 2... 118 70-44
gi|174278881|gb|U00000.1| (AR010154) serine/threonine-specific kinase 2... 149 60-41
gi|174278881|gb|U00000.1| (AR010154) serine/threonine-specific kinase 2... 165 70-40
gi|174278881|gb|U00000.1| (AR010154) serine/threonine-specific kinase 2... 132 60-39
gi|174278881|gb|U00000.1| (AR010154) serine/threonine-specific kinase 2... 131 20-29
gi|174278881|gb|U00000.1| (AR010154) serine/threonine-specific kinase 2... 130 20-28
gi|174278881|gb|U00000.1| (AR010154) serine/threonine-specific kinase 2... 129 70-29
gi|174278881|gb|U00000.1| (AR010154) serine/threonine-specific kinase 2... 128 70-28

Tissue: HUMAN

Human Brain

Human Placenta

Human Kidney

Human Heart

WO 01/88148 A2



NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES THEREOF

RELATED APPLICATIONS

The present application claims priority to U.S. Serial No. 09/816,094, filed March 26, 2001 (Atty. Docket CL000536-CIP), which is a continuation-in-part of U.S. Serial No. 09/734,032, filed December 12, 2000 (Atty. Docket CL000536) and U.S. Serial No. 60/205,228, filed May 17, 2000 (Atty. Docket CL000536-PROV).

FIELD OF THE INVENTION

The present invention is in the field of kinase proteins that are related to the protein kinase N (PKN) kinase subfamily, recombinant DNA molecules, and protein production. The present invention specifically provides novel peptides and proteins that effect protein phosphorylation and nucleic acid molecules encoding such peptide and protein molecules, all of which are useful in the development of human therapeutics and diagnostic compositions and methods.

BACKGROUND OF THE INVENTION

Protein Kinases

Kinases regulate many different cell proliferation, differentiation, and signaling processes by adding phosphate groups to proteins. Uncontrolled signaling has been implicated in a variety of disease conditions including inflammation, cancer, arteriosclerosis, and psoriasis. Reversible protein phosphorylation is the main strategy for controlling activities of eukaryotic cells. It is estimated that more than 1000 of the 10,000 proteins active in a typical mammalian cell are phosphorylated. The high energy phosphate, which drives activation, is generally transferred from adenosine triphosphate molecules (ATP) to a particular protein by protein kinases and removed from that protein by protein phosphatases. Phosphorylation occurs in response to extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc), cell cycle checkpoints, and environmental or nutritional stresses and is roughly analogous to turning on a molecular switch. When the switch goes on, the appropriate protein kinase activates a metabolic enzyme, regulatory protein, receptor, cytoskeletal protein, ion channel or pump, or transcription factor.

The kinases comprise the largest known protein group, a superfamily of enzymes with widely varied functions and specificities. They are usually named after their substrate, their regulatory molecules, or some aspect of a mutant phenotype. With regard to substrates, the protein kinases may be roughly divided into two groups; those that phosphorylate tyrosine residues (protein tyrosine kinases, PTK) and those that phosphorylate serine or threonine residues (serine/threonine kinases, STK). A few protein kinases have dual specificity and phosphorylate threonine and tyrosine residues. Almost all kinases contain a similar 250-300 amino acid catalytic domain. The N-terminal domain, which contains subdomains I-IV, generally folds into a two-lobed structure, which binds and orients the ATP (or GTP) donor molecule. The larger C terminal lobe, which contains subdomains VI A-XI, binds the protein substrate and carries out the transfer of the gamma phosphate from ATP to the hydroxyl group of a serine, threonine, or tyrosine residue. Subdomain V spans the two lobes.

The kinases may be categorized into families by the different amino acid sequences (generally between 5 and 100 residues) located on either side of, or inserted into loops of, the kinase domain. These added amino acid sequences allow the regulation of each kinase as it recognizes and interacts with its target protein. The primary structure of the kinase domains is conserved and can be further subdivided into 11 subdomains. Each of the 11 subdomains contains specific residues and motifs or patterns of amino acids that are characteristic of that subdomain and are highly conserved (Hardie, G. and Hanks, S. (1995) *The Protein Kinase Facts Books*, Vol I:7-20 Academic Press, San Diego, Calif.).

The second messenger dependent protein kinases primarily mediate the effects of second messengers such as cyclic AMP (cAMP), cyclic GMP, inositol triphosphate, phosphatidylinositol, 3,4,5-triphosphate, cyclic-ADPribose, arachidonic acid, diacylglycerol and calcium-calmodulin. The cyclic-AMP dependent protein kinases (PKA) are important members of the STK family. Cyclic-AMP is an intracellular mediator of hormone action in all prokaryotic and animal cells that have been studied. Such hormone-induced cellular responses include thyroid hormone secretion, cortisol secretion, progesterone secretion, glycogen breakdown, bone resorption, and regulation of heart rate and force of heart muscle contraction. PKA is found in all animal cells and is thought to account for the effects of cyclic-AMP in most of these cells. Altered PKA expression is implicated in a variety of disorders and diseases including cancer, thyroid disorders, diabetes, atherosclerosis, and cardiovascular disease (Isselbacher, K. J. *et al.* (1994) *Harrison's Principles of Internal Medicine*, McGraw-Hill, New York, N.Y., pp. 416-431, 1887).

Calcium-calmodulin (CaM) dependent protein kinases are also members of STK family. Calmodulin is a calcium receptor that mediates many calcium regulated processes by binding to

target proteins in response to the binding of calcium. The principle target protein in these processes is CaM dependent protein kinases. CaM-kinases are involved in regulation of smooth muscle contraction (MLC kinase), glycogen breakdown (phosphorylase kinase), and neurotransmission (CaM kinase I and CaM kinase II). CaM kinase I phosphorylates a variety of substrates including the neurotransmitter related proteins synapsin I and II, the gene transcription regulator, CREB, and the cystic fibrosis conductance regulator protein, CFTR (Haribabu, B. *et al.* (1995) *EMBO Journal* 14:3679-86). CaM II kinase also phosphorylates synapsin at different sites, and controls the synthesis of catecholamines in the brain through phosphorylation and activation of tyrosine hydroxylase. Many of the CaM kinases are activated by phosphorylation in addition to binding to CaM. The kinase may autophosphorylate itself, or be phosphorylated by another kinase as part of a "kinase cascade".

Another ligand-activated protein kinase is 5'-AMP-activated protein kinase (AMPK) (Gao, G. *et al.* (1996) *J. Biol. Chem.* 15:8675-81). Mammalian AMPK is a regulator of fatty acid and sterol synthesis through phosphorylation of the enzymes acetyl-CoA carboxylase and hydroxymethylglutaryl-CoA reductase and mediates responses of these pathways to cellular stresses such as heat shock and depletion of glucose and ATP. AMPK is a heterotrimeric complex comprised of a catalytic alpha subunit and two non-catalytic beta and gamma subunits that are believed to regulate the activity of the alpha subunit. Subunits of AMPK have a much wider distribution in non-lipogenic tissues such as brain, heart, spleen, and lung than expected. This distribution suggests that its role may extend beyond regulation of lipid metabolism alone.

The mitogen-activated protein kinases (MAP) are also members of the STK family. MAP kinases also regulate intracellular signaling pathways. They mediate signal transduction from the cell surface to the nucleus via phosphorylation cascades. Several subgroups have been identified, and each manifests different substrate specificities and responds to distinct extracellular stimuli (Egan, S. E. and Weinberg, R. A. (1993) *Nature* 365:781-783). MAP kinase signaling pathways are present in mammalian cells as well as in yeast. The extracellular stimuli that activate mammalian pathways include epidermal growth factor (EGF), ultraviolet light, hyperosmolar medium, heat shock, endotoxic lipopolysaccharide (LPS), and pro-inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1).

PRK (proliferation-related kinase) is a serum/cytokine inducible STK that is involved in regulation of the cell cycle and cell proliferation in human megakaryotic cells (Li, B. *et al.* (1996) *J. Biol. Chem.* 271:19402-8). PRK is related to the polo (derived from humans polo gene) family of STKs implicated in cell division. PRK is downregulated in lung tumor tissue and may be a proto-oncogene whose deregulated expression in normal tissue leads to oncogenic transformation. Altered

MAP kinase expression is implicated in a variety of disease conditions including cancer, inflammation, immune disorders, and disorders affecting growth and development.

The cyclin-dependent protein kinases (CDKs) are another group of STKs that control the progression of cells through the cell cycle. Cyclins are small regulatory proteins that act by binding to and activating CDKs that then trigger various phases of the cell cycle by phosphorylating and activating selected proteins involved in the mitotic process. CDKs are unique in that they require multiple inputs to become activated. In addition to the binding of cyclin, CDK activation requires the phosphorylation of a specific threonine residue and the dephosphorylation of a specific tyrosine residue.

Protein tyrosine kinases, PTKs, specifically phosphorylate tyrosine residues on their target proteins and may be divided into transmembrane, receptor PTKs and nontransmembrane, non-receptor PTKs. Transmembrane protein-tyrosine kinases are receptors for most growth factors. Binding of growth factor to the receptor activates the transfer of a phosphate group from ATP to selected tyrosine side chains of the receptor and other specific proteins. Growth factors (GF) associated with receptor PTKs include; epidermal GF, platelet-derived GF, fibroblast GF, hepatocyte GF, insulin and insulin-like GFs, nerve GF, vascular endothelial GF, and macrophage colony stimulating factor.

Non-receptor PTKs lack transmembrane regions and, instead, form complexes with the intracellular regions of cell surface receptors. Such receptors that function through non-receptor PTKs include those for cytokines, hormones (growth hormone and prolactin) and antigen-specific receptors on T and B lymphocytes.

Many of these PTKs were first identified as the products of mutant oncogenes in cancer cells where their activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs, and it is well known that cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (Carbonneau H and Tonks NK (1992) *Annu. Rev. Cell. Biol.* 8:463-93). Regulation of PTK activity may therefore be an important strategy in controlling some types of cancer.

Protein kinase N ("PKN") is a serine/threonine protein kinase with a catalytic domain homologous to those of PKC family members. (Mukai, H. and Ono, Y. (1994) *C. Biochem. Biophys. Res. Commun.* 199, 897-904). Experimental data suggests that its kinase activity is enhanced by fatty acids such as arachidonic acid and small GTP-binding protein Rho in a GTP-dependent manner.

Experimental data indicates that PKN is a target for human papilloma virus ("HPV") E6 protein. These data suggest that binding to PKN is required for immortalizing normal mammary epithelial cells (Gao, et al. (2000) J Biol Chem May 19;275(20):14824-14830.)

PKN plays a role in neuron-specific transcription regulation. Results indicate that PKN interacts with a neuron-specific basic helix-loop-helix transcription factor, NDRF/NeuroD2, suggesting that PKN may contribute to transcriptional responses through the post-translational modification of the NDRF/NeuroD2-dependent transcriptional machinery. Furthermore, PKN may play a role in Alzheimer's disease. Results indicate that PKN accumulates in Alzheimer neurofibrillary tangles ("NFTs") and associated endoplasmic reticulum-derived vesicles and phosphorylates tau protein. These results suggest a specific role for PKN in NFT formation and neurodegeneration in Alzheimer's damaged neurons.

Because PKN has been implicated in pathologies ranging from neurodegeneration to cancer, discovery of a novel PKN gene can result in development of treatments for a wide range of pathologies. For further discussion of PKN, see Kitagawa, M., et al. (1995) Biochem. J. 310, 657-664; Mukai, H., et al. (1994) Biochem. Biophys. Res. Commun. 204, 348-356; Amano, M., et al. (1996) Science 271, 648-650; Shibata, H., et al. (1996) FEBS Lett. 385, 221-224; Watanabe, G., et al. (1996) Science 271, 645-648; Yoshinaga et al. (1999) J. Biochem. 126, 475-484; Hashimoto, et al., (1998) Mol.Brain.Res. 59 143-153; Shibata, et al., (1999) Brain Res Mol Brain Res Dec 10;74(1-2):126-34; and Kawamata, et al., (1998) J Neurosci Sep 15;18(18):7402-10.

Kinase proteins, particularly members of the PKN kinase subfamily, are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown members of this subfamily of kinase proteins. The present invention advances the state of the art by providing previously unidentified human kinase proteins that have homology to members of the PKN kinase subfamily.

SUMMARY OF THE INVENTION

The present invention is based in part on the identification of amino acid sequences of human kinase peptides and proteins that are related to the PKN kinase subfamily, as well as allelic variants and other mammalian orthologs thereof. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate kinase activity in cells and tissues that express the kinase. Experimental data as provided in Figure 1 indicates expression in the human brain, human placenta, human kidney, human heart.

DESCRIPTION OF THE FIGURE SHEETS

FIGURE 1 provides the nucleotide sequence of a cDNA molecule that encodes the kinase protein of the present invention. (SEQ ID NO:1) In addition, structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of inventions based on this molecular sequence. Experimental data as provided in Figure 1 indicates expression in the human brain, human placenta, human kidney, human heart.

FIGURE 2 provides the predicted amino acid sequence of the kinase of the present invention. (SEQ ID NO:2) In addition structure and functional information such as protein family, function, and modification sites is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence.

FIGURE 3 provides genomic sequences that span the gene encoding the kinase protein of the present invention. (SEQ ID NO:3) In addition structure and functional information, such as intron/exon structure, promoter location, etc., is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence. As illustrated in Figure 3, SNPs, including 3 insertion/deletion variants ("indels"), were identified at 7 different nucleotide positions.

DETAILED DESCRIPTION OF THE INVENTION

General Description

The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a kinase protein or part of a kinase protein and are related to the PKN kinase subfamily. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human kinase peptides and proteins that are related to the PKN kinase subfamily, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these kinase peptides and proteins, nucleic acid variation (allelic information), tissue distribution of expression, and information about the closest art known

protein/peptide/domain that has structural or sequence homology to the kinase of the present invention.

In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known kinase proteins of the PKN kinase subfamily and the expression pattern observed. Experimental data as provided in Figure 1 indicates expression in the human brain, human placenta, human kidney, human heart. The art has clearly established the commercial importance of members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known PKN family or subfamily of kinase proteins.

Specific Embodiments

Peptide Molecules

The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the kinase family of proteins and are related to the PKN kinase subfamily (protein sequences are provided in Figure 2, transcript/cDNA sequences are provided in Figure 1 and genomic sequences are provided in Figure 3). The peptide sequences provided in Figure 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the information in Figure 3, will be referred herein as the kinase peptides of the present invention, kinase peptides, or peptides/proteins of the present invention.

The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprise the amino acid sequences of the kinase peptides disclosed in the Figure 2, (encoded by the nucleic acid molecule shown in Figure 1, transcript/cDNA or Figure 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

As used herein, a peptide is said to be "isolated" or "purified" when it is substantially free of cellular material or free of chemical precursors or other chemicals. The peptides of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of

the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

In some uses, "substantially free of cellular material" includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of the kinase peptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

The isolated kinase peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. Experimental data as provided in Figure 1 indicates expression in the human brain, human placenta, human kidney, human heart. For example, a nucleic acid molecule encoding the kinase peptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Many of these techniques are described in detail below.

Accordingly, the present invention provides proteins that consist of the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). The amino acid sequence of such a protein is provided in Figure 2. A protein consists of an amino acid sequence when the amino acid sequence is the final amino acid sequence of the protein.

The present invention further provides proteins that consist essentially of the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example from about

1 to about 100 or so additional residues, typically from 1 to about 20 additional residues in the final protein.

The present invention further provides proteins that comprise the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). A protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein can be only the peptide or have additional amino acid molecules, such as amino acid residues (contiguous encoded sequence) that are naturally associated with it or heterologous amino acid residues/peptide sequences. Such a protein can have a few additional amino acid residues or can comprise several hundred or more additional amino acids. The preferred classes of proteins that are comprised of the kinase peptides of the present invention are the naturally occurring mature proteins. A brief description of how various types of these proteins can be made/isolated is provided below.

The kinase peptides of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a kinase peptide operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the kinase peptide. "Operatively linked" indicates that the kinase peptide and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the kinase peptide.

In some uses, the fusion protein does not affect the activity of the kinase peptide *per se*. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant kinase peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see Ausubel *et al.*, *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a

fusion moiety (e.g., a GST protein). A kinase peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the kinase peptide.

As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the kinase peptides of the present invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part 1*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence*

Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., *et al.*, *Nucleic Acids Res.* 12(1):387 (1984)) (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (*J. Mol. Biol.* 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (*Nucleic Acids Res.* 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the kinase peptides of the present invention as well as being encoded by the same genetic locus as the kinase peptide provided herein. Mapping position in Figure 3 shows that the kinase of the present invention is encoded by a gene on chromosome 16 near markers SHGC-10032 (LOD scores of 12.45), SHGC-11302 (LOD scores of 12.1), SHGC-6754 (LOD scores of 11.48), SHGC-57443 (LOD score of 9.08), SHGC-295 (LOD score of 7.79).

Allelic variants of a kinase peptide can readily be identified as being a human protein having a high degree (significant) of sequence homology/identity to at least a portion of the kinase peptide as

well as being encoded by the same genetic locus as the kinase peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in Figure 3, such as the genomic sequence mapped to the reference human. Mapping position in Figure 3 shows that the kinase of the present invention is encoded by a gene on chromosome 16 near markers SHGC-10032 (LOD scores of 12.45), SHGC-11302 (LOD scores of 12.1), SHGC-6754 (LOD scores of 11.48), SHGC-57443 (LOD score of 9.08), SHGC-295 (LOD score of 7.79). As used herein, two proteins (or a region of the proteins) have significant homology when the amino acid sequences are typically at least about 70-80%, 80-90%, and more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under stringent conditions as more fully described below.

Figure 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 7 different nucleotide positions in introns and regions 5' and 3' of the ORF. Such SNPs in introns and outside the ORF may affect control/regulatory elements.

Paralogs of a kinase peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the kinase peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

Orthologs of a kinase peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the kinase peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a kinase peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

Non-naturally occurring variants of the kinase peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the kinase peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a kinase peptide by another amino acid of like characteristics. Typically seen as

conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie *et al.*, *Science* 247:1306-1310 (1990).

Variant kinase peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind substrate, ability to phosphorylate substrate, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. Figure 2 provides the result of protein analysis and can be used to identify critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham *et al.*, *Science* 244:1081-1085 (1989)), particularly using the results provided in Figure 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as kinase activity or in assays such as an *in vitro* proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith *et al.*, *J. Mol. Biol.* 224:899-904 (1992); de Vos *et al.* *Science* 255:306-312 (1992)).

The present invention further provides fragments of the kinase peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in Figure 2. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous amino acid residues from a kinase peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the kinase peptide or could be chosen for the ability to perform a function, e.g. bind a substrate or act as an immunogen. Particularly important fragments are biologically active fragments, peptides that are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the kinase peptide, e.g., active site, a

transmembrane domain or a substrate-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known and readily available to those of skill in the art (e.g., PROSITE analysis). The results of one such analysis are provided in Figure 2.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common modifications that occur naturally in kinase peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in Figure 2).

Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Such modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as *Proteins - Structure and Molecular Properties*, 2nd Ed., T.E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., *Posttranslational Covalent Modification of Proteins*, B.C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter *et al.* (*Meth. Enzymol.* 182: 626-646 (1990)) and Rattan *et al.* (*Ann. N.Y. Acad. Sci.* 663:48-62 (1992)).

Accordingly, the kinase peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature kinase peptide is fused with another compound, such as a compound to increase the half-life of the kinase peptide (for example, polyethylene glycol), or in

which the additional amino acids are fused to the mature kinase peptide, such as a leader or secretory sequence or a sequence for purification of the mature kinase peptide or a pro-protein sequence.

Protein/Peptide Uses

The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or ligand) in biological fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein or ligand (such as, for example, in a kinase-effector protein interaction or kinase-ligand interaction), the protein can be used to identify the binding partner/ligand so as to develop a system to identify inhibitors of the binding interaction. Any or all of these uses are capable of being developed into reagent grade or kit format for commercialization as commercial products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

Substantial chemical and structural homology exists between the PKN protein described herein and rat serin/threonine protein kinase, which is also rich in brain (see Figure 1). As discussed in the background, rat serin/threonine protein kinase are known in the art that it accumulates in Alzheimer neurofibrillary tangles ("NFTs") and associated endoplasmic reticulum-derived vesicles and phosphorylates tau protein. It also plays a role in neuron-specific transcription regulation and may play a role in Alzheimer's disease. Accordingly, the PKN protein, and the encoding gene, provided by the present invention is useful for treating, preventing, and/or diagnosing neurodegenerative diseases and cancer.

The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, kinases isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the kinase. Experimental data as provided in Figure 1 indicates that kinase proteins of the present invention are expressed in the human brain, human

placenta, human kidney, human heart by PCR-based tissue screening panel. A large percentage of pharmaceutical agents are being developed that modulate the activity of kinase proteins, particularly members of the PKN subfamily (see Background of the Invention). The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention, particularly in combination with the expression information provided in Figure 1. Experimental data as provided in Figure 1 indicates expression in the human brain, human placenta, human kidney, human heart. Such uses can readily be determined using the information provided herein, that which is known in the art, and routine experimentation.

The proteins of the present invention (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to kinases that are related to members of the PKN subfamily. Such assays involve any of the known kinase functions or activities or properties useful for diagnosis and treatment of kinase-related conditions that are specific for the subfamily of kinases that the one of the present invention belongs to, particularly in cells and tissues that express the kinase. Experimental data as provided in Figure 1 indicates that kinase proteins of the present invention are expressed in the human brain, human placenta, human kidney, human heart by PCR-based tissue screening panel.

The proteins of the present invention are also useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the kinase, as a biopsy or expanded in cell culture. Experimental data as provided in Figure 1 indicates expression in the human brain, human placenta, human kidney, human heart. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the kinase protein.

The polypeptides can be used to identify compounds that modulate kinase activity of the protein in its natural state or an altered form that causes a specific disease or pathology associated with the kinase. Both the kinases of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the kinase. These compounds can be further screened against a functional kinase to determine the effect of the compound on the kinase activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate (antagonist) the kinase to a desired degree.

Further, the proteins of the present invention can be used to screen a compound for the ability to stimulate or inhibit interaction between the kinase protein and a molecule that normally interacts with the kinase protein, e.g. a substrate or a component of the signal pathway that the kinase protein normally interacts (for example, another kinase). Such assays typically include the steps of combining the kinase protein with a candidate compound under conditions that allow the kinase protein, or

fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the kinase protein and the target, such as any of the associated effects of signal transduction such as protein phosphorylation, cAMP turnover, and adenylate cyclase activation, etc.

Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam *et al.*, *Nature* 354:82-84 (1991); Houghten *et al.*, *Nature* 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang *et al.*, *Cell* 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')₂, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

One candidate compound is a soluble fragment of the receptor that competes for substrate binding. Other candidate compounds include mutant kinases or appropriate fragments containing mutations that affect kinase function and thus compete for substrate. Accordingly, a fragment that competes for substrate, for example with a higher affinity, or a fragment that binds substrate but does not allow release, is encompassed by the invention.

The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) kinase activity. The assays typically involve an assay of events in the signal transduction pathway that indicate kinase activity. Thus, the phosphorylation of a substrate, activation of a protein, a change in the expression of genes that are up- or down-regulated in response to the kinase protein dependent signal cascade can be assayed.

Any of the biological or biochemical functions mediated by the kinase can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly Figure 2. Specifically, a biological function of a cell or tissues that expresses the kinase can be assayed. Experimental data as provided in Figure 1 indicates that kinase proteins of the present invention are expressed in the human brain, human placenta, human kidney, human heart by PCR-based tissue screening panel.

Binding and/or activating compounds can also be screened by using chimeric kinase proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or

extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a substrate-binding region can be used that interacts with a different substrate than that which is recognized by the native kinase. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the kinase is derived.

The proteins of the present invention are also useful in competition binding assays in methods designed to discover compounds that interact with the kinase (e.g. binding partners and/or ligands). Thus, a compound is exposed to a kinase polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble kinase polypeptide is also added to the mixture. If the test compound interacts with the soluble kinase polypeptide, it decreases the amount of complex formed or activity from the kinase target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the kinase. Thus, the soluble polypeptide that competes with the target kinase region is designed to contain peptide sequences corresponding to the region of interest.

To perform cell free drug screening assays, it is sometimes desirable to immobilize either the kinase protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ³⁵S-labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of kinase-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein trapped in the wells by antibody conjugation. Preparations of a kinase-binding protein and a candidate compound are incubated in the kinase protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described

above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the kinase protein target molecule, or which are reactive with kinase protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

Agents that modulate one of the kinases of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

Modulators of kinase protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the kinase pathway, by treating cells or tissues that express the kinase. Experimental data as provided in Figure 1 indicates expression in the human brain, human placenta, human kidney, human heart. These methods of treatment include the steps of administering a modulator of kinase activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

In yet another aspect of the invention, the kinase proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with the kinase and are involved in kinase activity. Such kinase-binding proteins are also likely to be involved in the propagation of signals by the kinase proteins or kinase targets as, for example, downstream elements of a kinase-mediated signaling pathway. Alternatively, such kinase-binding proteins are likely to be kinase inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a kinase protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a kinase-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional

transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the kinase protein.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a kinase-modulating agent, an antisense kinase nucleic acid molecule, a kinase-specific antibody, or a kinase-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal or other model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

The kinase proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism. Experimental data as provided in Figure 1 indicates expression in the human brain, human placenta, human kidney, human heart. The method involves contacting a biological sample with a compound capable of interacting with the kinase protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A biological sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered kinase activity in cell-based or cell-free assay, alteration in substrate or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

In vitro techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can be detected *in vivo* in a subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (*Clin. Exp. Pharmacol. Physiol.* 23(10-11):983-985 (1996)), and Linder, M.W. (*Clin. Chem.* 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the kinase protein in which one or more of the kinase functions in one population is different from those in another population. The peptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other substrate-binding regions that are more or less active in substrate binding, and kinase activation. Accordingly, substrate dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic peptides could be identified.

The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Experimental data as provided in Figure 1 indicates expression in the human brain, human placenta, human kidney, human heart. Accordingly, methods for treatment include the use of the kinase protein or fragments.

Antibodies

The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective despite some degree of cross-reactivity.

As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab')₂, and Fv fragments.

Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, *Antibodies*, Cold Spring Harbor Press, (1989).

In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in Figure 2, and domain of sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

Antibodies are preferably prepared from regions or discrete fragments of the kinase proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity and/or kinase/binding partner interaction. Figure 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see Figure 2).

Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Antibody Uses

The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Experimental data as provided in Figure 1 indicates that kinase proteins of the present invention are expressed in the human brain, human placenta, human kidney, human heart by PCR-based tissue screening panel. Further, such antibodies can be used to detect protein *in situ*, *in vitro*, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal expression during development or progression of a biological condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Experimental data as provided in Figure 1 indicates expression in the human brain, human placenta, human kidney, human heart. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Experimental data as provided in Figure 1 indicates expression

in the human brain, human placenta, human kidney, human heart. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

The antibodies are also useful for tissue typing. Experimental data as provided in Figure 1 indicates expression in the human brain, human placenta, human kidney, human heart. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the kinase peptide to a binding partner such as a substrate. These uses can also be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites required for function or against intact protein that is associated with a cell or cell membrane. See Figure 2 for structural information relating to the proteins of the present invention.

The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nucleic acid arrays and similar methods have been developed for antibody arrays.

Nucleic Acid Molecules

The present invention further provides isolated nucleic acid molecules that encode a kinase peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes

one of the kinase peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

As used herein, an "isolated" nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5KB, 4KB, 3KB, 2KB, or 1KB or less, particularly contiguous peptide encoding sequences and peptide encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

Moreover, an "isolated" nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.

The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule.

The present invention further provides nucleic acid molecules that comprise the nucleotide sequences shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprises several hundred or more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

In Figures 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, humans genomic sequence (Figure 3) and cDNA/transcript sequences (Figure 1), the nucleic acid molecules in the Figures will contain genomic intronic sequences, 5' and 3' non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in Figures 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in situ*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the kinase peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5' and 3' sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid

molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

The invention further provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the kinase proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

The present invention further provides non-coding fragments of the nucleic acid molecules provided in Figures 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in developing screens to identify gene-modulating agents. A promoter can readily be identified as being 5' to the ATG start site in the genomic sequence provided in Figure 3.

A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could be at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers. Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

A probe/primer typically comprises substantially a purified oligonucleotide or oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence encoding a peptide that is typically 60-70%, 70-80%, 80-90%, and more typically at least about 90-95% or more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by genetic locus of the encoding gene. Mapping position in Figure 3 shows that the kinase of the present invention is encoded by a gene on chromosome 16 near markers SHGC-10032 (LOD scores of 12.45), SHGC-11302 (LOD scores of 12.1), SHGC-6754 (LOD scores of 11.48), SHGC-57443 (LOD score of 9.08), SHGC-295 (LOD score of 7.79).

Figure 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 7 different nucleotide positions in introns and regions 5' and 3' of the ORF. Such SNPs in introns and outside the ORF may affect control/regulatory elements.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60-70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. One example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65C. Examples of moderate to low stringency hybridization conditions are well known in the art.

Nucleic Acid Molecule Uses

The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in Figure 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in Figure 2. As illustrated in Figure 3, SNPs, including 3 insertion/deletion variants ("indels"), were identified at 7 different nucleotide positions.

The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5' noncoding regions, the coding region, and 3' noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

The nucleic acid molecules are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter *in situ* expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of *in situ* hybridization methods. Mapping position in Figure 3 shows that the kinase of the present invention is encoded by a gene on chromosome 16 near markers SHGC-10032 (LOD scores of 12.45), SHGC-11302 (LOD scores of 12.1), SHGC-6754 (LOD scores of 11.48), SHGC-57443 (LOD score of 9.08), SHGC-295 (LOD score of 7.79).

The nucleic acid molecules are also useful in making vectors containing the gene regulatory regions of the nucleic acid molecules of the present invention.

The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful as hybridization probes for determining the presence, level, form and distribution of nucleic acid expression. Experimental data as provided in Figure 1 indicates that kinase proteins of the present invention are expressed in the human brain, human placenta, human kidney, human heart by PCR-based tissue screening panel. Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA.

Accordingly, probes corresponding to the peptides described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in kinase protein expression relative to normal results.

In vitro techniques for detection of mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detecting DNA includes Southern hybridizations and *in situ* hybridization.

Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a kinase protein, such as by measuring a level of a kinase-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a kinase gene has been mutated. Experimental data as provided in Figure 1 indicates that kinase proteins of the present invention are expressed in the human brain, human placenta, human kidney, human heart by PCR-based tissue screening panel.

Nucleic acid expression assays are useful for drug screening to identify compounds that modulate kinase nucleic acid expression.

The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the kinase gene, particularly biological and pathological processes that are mediated by the kinase in cells and tissues that express it. Experimental data as provided in Figure 1 indicates expression in the human brain, human placenta, human kidney, human heart. The method typically includes assaying the ability of the compound to modulate the expression of the kinase nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired kinase nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the kinase nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

The assay for kinase nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway. Further, the expression of genes that are up- or down-regulated in response to the kinase protein signal pathway can also be assayed. In this embodiment the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

Thus, modulators of kinase gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of kinase mRNA in the presence of the candidate compound is compared to the level of expression of kinase mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of

mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate kinase nucleic acid expression in cells and tissues that express the kinase. Experimental data as provided in Figure 1 indicates that kinase proteins of the present invention are expressed in the human brain, human placenta, human kidney, human heart by PCR-based tissue screening panel. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) or nucleic acid expression.

Alternatively, a modulator for kinase nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the kinase nucleic acid expression in the cells and tissues that express the protein. Experimental data as provided in Figure 1 indicates expression in the human brain, human placenta, human kidney, human heart.

The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the kinase gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in kinase nucleic acid expression, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in kinase genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally occurring genetic mutations in the kinase gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the kinase gene associated with a dysfunction

provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a kinase protein.

Individuals carrying mutations in the kinase gene can be detected at the nucleic acid level by a variety of techniques. Figure 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 7 different nucleotide positions in introns and regions 5' and 3' of the ORF. Such SNPs in introns and outside the ORF may affect control/regulatory elements. Mapping position in Figure 3 shows that the kinase of the present invention is encoded by a gene on chromosome 16 near markers SHGC-10032 (LOD scores of 12.45), SHGC-11302 (LOD scores of 12.1), SHGC-6754 (LOD scores of 11.48), SHGC-57443 (LOD score of 9.08), SHGC-295 (LOD score of 7.79). Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran *et al.*, *Science* 241:1077-1080 (1988); and Nakazawa *et al.*, *PNAS* 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya *et al.*, *Nucleic Acids Res.* 23:675-682 (1995)). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

Alternatively, mutations in a kinase gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

Further, sequence-specific ribozymes (U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant kinase gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays

(Naeve, C.W., (1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen *et al.*, *Adv. Chromatogr.* 36:127-162 (1996); and Griffin *et al.*, *Appl. Biochem. Biotechnol.* 38:147-159 (1993)).

Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers *et al.*, *Science* 230:1242 (1985)); Cotton *et al.*, *PNAS* 85:4397 (1988); Saleeba *et al.*, *Meth. Enzymol.* 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita *et al.*, *PNAS* 86:2766 (1989); Cotton *et al.*, *Mutat. Res.* 285:125-144 (1993); and Hayashi *et al.*, *Genet. Anal. Tech. Appl.* 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers *et al.*, *Nature* 313:495 (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the kinase gene in an individual in order to select an appropriate compound or dosage regimen for treatment. Figure 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 7 different nucleotide positions in introns and regions 5' and 3' of the ORF. Such SNPs in introns and outside the ORF may affect control/regulatory elements.

Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The nucleic acid molecules are thus useful as antisense constructs to control kinase gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of kinase protein. An antisense RNA or DNA nucleic acid molecule would hybridize to the mRNA and thus block translation of mRNA into kinase protein.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of kinase nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired kinase nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more

regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the kinase protein, such as substrate binding.

The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in kinase gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered *ex vivo* and returned to the patient, are introduced into an individual where the cells produce the desired kinase protein to treat the individual.

The invention also encompasses kits for detecting the presence of a kinase nucleic acid in a biological sample. Experimental data as provided in Figure 1 indicates that kinase proteins of the present invention are expressed in the human brain, human placenta, human kidney, human heart by PCR-based tissue screening panel. For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting kinase nucleic acid in a biological sample; means for determining the amount of kinase nucleic acid in the sample; and means for comparing the amount of kinase nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect kinase protein mRNA or DNA.

Nucleic Acid Arrays

The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in Figures 1 and 3 (SEQ ID NOS:1 and 3).

As used herein "Arrays" or "Microarrays" refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is prepared and used according to the methods described in US Patent 5,837,832, Chee *et al.*, PCT application W095/11995 (Chee *et al.*), Lockhart, D. J. *et al.* (1996; Nat. Biotech. 14: 1675-1680) and Schena, M. *et al.* (1996; Proc. Natl. Acad. Sci. 93: 10614-10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown *et al.*, US Patent No. 5,807,522.

The microarray or detection kit is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be preferable to use oligonucleotides

that are only 7-20 nucleotides in length. The microarray or detection kit may contain oligonucleotides that cover the known 5', or 3', sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

In order to produce oligonucleotides to a known sequence for a microarray or detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5' or at the 3' end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The "pairs" will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler *et al.*) which is incorporated herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of

nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large-scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

Using such arrays, the present invention provides methods to identify the expression of the kinase proteins/peptides of the present invention. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the present invention and or alleles of the kinase gene of the present invention. Figure 3 provides information on SNPs that have been found in the gene encoding the kinase protein of the present invention. SNPs were identified at 7 different nucleotide positions in introns and regions 5' and 3' of the ORF. Such SNPs in introns and outside the ORF may affect control/regulatory elements.

Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, *An Introduction to Radioimmunoassay and Related Techniques*, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. *et al.*, *Techniques in Immunocytochemistry*, Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., *Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in the art will readily recognize that the previously unidentified kinase gene of the present invention can be routinely identified using the sequence information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

Vectors/host cells

The invention also provides vectors containing the nucleic acid molecules described herein. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid molecules when the host cell replicates.

The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).

Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ , the lac, TRP, and TAC promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, *E. coli*, *Streptomyces*, and *Salmonella typhimurium*. Eukaryotic cells include, but are not limited to, yeast, insect cells such as *Drosophila*, animal cells such as COS and CHO cells, and plant cells.

As described herein, it may be desirable to express the peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Smith *et al.*, *Gene* 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, *Gene* 69:301-315 (1988)) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185:60-89 (1990)).

Recombinant protein expression can be maximized in host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example *E. coli*. (Wada *et al.*, *Nucleic Acids Res.* 20:2111-2118 (1992)).

The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, *EMBO J.* 6:229-234 (1987)), pMFa (Kurjan *et al.*, *Cell* 30:933-943(1982)), pJRY88 (Schultz *et al.*, *Gene* 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, CA).

The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith *et al.*, *Mol. Cell Biol.* 3:2156-2165 (1983)) and the pVL series (Lucklow *et al.*, *Virology* 170:31-39 (1989)).

In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. *Nature* 329:840(1987)) and pMT2PC (Kaufman *et al.*, *EMBO J.* 6:187-195 (1987)).

The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques

such as those found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

Where secretion of the peptide is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as kinases, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

Where the peptide is not secreted into the medium, which is typically the case with kinases, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may include an initial modified methionine in some cases as a result of a host-mediated process.

Uses of vectors and host cells

The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a kinase protein or peptide that can be further purified to produce desired amounts of kinase protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

Host cells are also useful for conducting cell-based assays involving the kinase protein or kinase protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native kinase protein is useful for assaying compounds that stimulate or inhibit kinase protein function.

Host cells are also useful for identifying kinase protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant kinase protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native kinase protein.

Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for studying the function of a kinase protein and identifying and evaluating modulators of kinase protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the kinase protein nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already

included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the kinase protein to particular cells.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder *et al.*, U.S. Patent No. 4,873,191 by Wagner *et al.* and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso *et al. PNAS* 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of *S. cerevisiae* (O'Gorman *et al. Science* 251:1351-1355 (1991)). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein is required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. *et al. Nature* 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an *in vivo* context. Accordingly, the various

physiological factors that are present *in vivo* and that could effect substrate binding, kinase protein activation, and signal transduction, may not be evident from *in vitro* cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay *in vivo* kinase protein function, including substrate interaction, the effect of specific mutant kinase proteins on kinase protein function and substrate interaction, and the effect of chimeric kinase proteins. It is also possible to assess the effect of null mutations, that is, mutations that substantially or completely eliminate one or more kinase protein functions.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

Claims

That which is claimed is:

1. An isolated peptide consisting of an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence shown in SEQ ID NO:2;
 - (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
 - (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and
 - (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
2. An isolated peptide comprising an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence shown in SEQ ID NO:2;
 - (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
 - (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and
 - (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
3. An isolated antibody that selectively binds to a peptide of claim 2.

4. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and
- (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

5. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and
- (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

6. A gene chip comprising a nucleic acid molecule of claim 5.

7. A transgenic non-human animal comprising a nucleic acid molecule of claim 5.

8. A nucleic acid vector comprising a nucleic acid molecule of claim 5.
9. A host cell containing the vector of claim 8.
10. A method for producing any of the peptides of claim 1 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
11. A method for producing any of the peptides of claim 2 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
12. A method for detecting the presence of any of the peptides of claim 2 in a sample, said method comprising contacting said sample with a detection agent that specifically allows detection of the presence of the peptide in the sample and then detecting the presence of the peptide.
13. A method for detecting the presence of a nucleic acid molecule of claim 5 in a sample, said method comprising contacting the sample with an oligonucleotide that hybridizes to said nucleic acid molecule under stringent conditions and determining whether the oligonucleotide binds to said nucleic acid molecule in the sample.
14. A method for identifying a modulator of a peptide of claim 2, said method comprising contacting said peptide with an agent and determining if said agent has modulated the function or activity of said peptide.
15. The method of claim 14, wherein said agent is administered to a host cell comprising an expression vector that expresses said peptide.
16. A method for identifying an agent that binds to any of the peptides of claim 2, said method comprising contacting the peptide with an agent and assaying the contacted mixture to determine whether a complex is formed with the agent bound to the peptide.
17. A pharmaceutical composition comprising an agent identified by the method of claim 16 and a pharmaceutically acceptable carrier therefor.

18. A method for treating a disease or condition mediated by a human kinase protein, said method comprising administering to a patient a pharmaceutically effective amount of an agent identified by the method of claim 16.

19. A method for identifying a modulator of the expression of a peptide of claim 2, said method comprising contacting a cell expressing said peptide with an agent, and determining if said agent has modulated the expression of said peptide.

20. An isolated human kinase peptide having an amino acid sequence that shares at least 70% homology with an amino acid sequence shown in SEQ ID NO:2.

21. A peptide according to claim 20 that shares at least 90 percent homology with an amino acid sequence shown in SEQ ID NO:2.

22. An isolated nucleic acid molecule encoding a human kinase peptide, said nucleic acid molecule sharing at least 80 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 or 3.

23. A nucleic acid molecule according to claim 22 that shares at least 90 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 or 3.

1/9

```

1   GGGAGCGCAG CCCGGGCGGG CGCCGGGGCC GGGGCCGAG CGCCAGGCGG
51  AGCGCGAGCT GGAGCCGCAG CCGGAGCCCG GGCCAGGCCG GGGGCCGGGA
101 GCGCAGGGCC GGGCTGCTCG TAGCGGCGGC GACCGAGCCC CCCAGCGGCT
151 GAGGGGCTTC CAGCGCCCGC CGGTGGCCGG GACCCACTAA AGCCCCCGCA
201 GCCGAGGAGT GCGGGGAGCC CCCTTCCACA TCCAGGATCC GGCGAGCCTC
251 GGGGAAGAGG GGGGGCCCTC CCGGATCCGA CACCGAGCGA CTCCCCTGCG
301 GGGAAAGCGG AGACTTCCTC GGTATTTAGA AGACAGCAAG CCCCTACGG
351 CACCGCAAGG ACTCCCCCTC CTCAGTCTGG GCCCCCGCCC CAAGACCTAG
401 AACGCAGTGC CCCAGGCCG GGATGCGAG AACCCCTCC CAAGATCCGG
451 TCATTACAAC TCCACACCTC AAGACAAGAA GACCCAGCTC AGAACGCCCC
501 TAGATCAGGG GATCCCAATT CCCCCCAACT CCGGTACATA GAAATCCCAA
551 ATCTAGGCAG CCGGGGACAG CAAGAGACAC TCTCACCAGC AAGAAGCCTC
601 GGGGATCCCC CCCCTAAAGC TCCAGGACTT GGGCGACTGA GCCCCTGGCG
651 GCACCGCTTG CACCCCGGTC CATGGTCGTG GCGCCCTGAG CCCCCGGGGC
701 CGGGCAGACG AAGACCGCGA CGGCGCCCAG GCCCCCTGCC GCGGCGTCCC
751 CGCGAGGCCA GCCAGGGAG AAGATGAGCG TGGGCTGCCC AGAGCCTGAG
801 CCGCCCGCT CCCTGACCTG CTGTGGGCGG GGGACTGCCC CTGGGCTTGG
851 TGCCGGTGTG CCCCTTCTCA CTGAAGACAT GCAGGCCCTG ACTCTCCGCA
901 CACTGGCCGC CAGCGACGTC ACCAAGCACT ACGAACTAGT CCGGGAGCTG
951 GGCAAAGGCA OCTATGGGAA GGTTGACCTG GTGGTCTACA AGGGCACAGG
1001 CACAAAATG GCACTGAAGT TTGTGAACAA GAGCAAAACC AAGCTGAAGA
1051 ACTTCCTACG GGAGGTGAGC ATCACCACAA GCCTCTCCTC CAGCCCTTTC
1101 ATCATCAAGG TCTTTGACGT GGTCTTTGAG ACAGAGGACT GCTACGTCTT
1151 TGCCACGAGG TACGCACCTG CTGGGGACCT GTTTGACATC ATCCCTCCCC
1201 AGGTGGGGCT CCCTGAGGAC ACGGTGAAGC GCTGTGTGCA GCAGCTGGGC
1251 CTGGCGCTGG ACTTCATGCA CGGGCGGCAG CTGGTGACAC GCGACATCAA
1301 GCCCGAGAAC GTGCTGCTGT TCGACCGCGA GTGCCGCCG GTAAAGCTGG
1351 CGGACTTCGG CATGACGCGC CGCGTGGGCT GCGCGCTCAA GCGCTGAGC
1401 GGCACCATCC CTTACACGGC GCCTGAGGTG TGCCAGGCGG GCCGCGCCGA
1451 CGGGCTGGCG GTGGACACGG GCGTGGACGT GTGGGCTTC GCGGTGCTCA
1501 TCTTCTGGGT GCTCACCGGC AACTTCCCGT GGGAGGCGGC GTCGGGCGCC
1551 GACGCTTCT TCGAGGAGTT CGTGCGCTGG CAGCGGGGCC GCCTGCCGGG
1601 GCTGCCCTCG CAGTGGCGCC GCTTCACCGA GCCCGCGCTG CGCATGTTCC
1651 AGCGCTTACT GGCCCTGGAG CCCGAGCGCC GCGGCCAGC CAAGGAGGTG
1701 TTCCGCTTCC TCAAGCACGA GCTCACGTCC GAGCTGCGCC GCCGGCCCTC
1751 GCACCGCGCG CGCAAGCCCC CCGGGGACCG CCCGCCCGCC GCCGGGCCAC
1801 TGCCCTCGA GCGCCTGGG CCGCTCAAGC GGACGGTGCT GACCGAGAGC
1851 GGCAGGGGCT CCCGGCCCGC GCCCCCGGCC GTGCGGTGCG TGCCCTTGCC
1901 CGTGCCGGTG CCGGTGCCAG TGCCCGTGCC GGTGCTGTG CCCGAGCCCG
1951 GCCTAGCTCC CCAGGGGCCC CCCGGCCGGA CCGACGGCCG CGCGGACAAG
2001 AGCAAAGGGC AGGTGGTGCT GGCCACGGCC ATCGAGATCT GCGTCTGAGT
2051 CGCCTCCGCC GCCCTCGGAC CCGGGAGCAG CCCGGGCCG CCCCAGCCG
2101 GTGCCCGGTG CGGCGGTAGG GAATGGAGCC ACCTCGCCG GGGGAGGGG
2151 GCGCAGCGGT AGACTAGGCA GGACGCGGCC CGGCACCTGG TCCGTCCCCG
2201 GCGGGCTGGT GAGGGGGCCA CCAAGAGCCC CTAGCGCGGC CTGGTGAGCG
2251 GGGGCTTGGC CCAGAGGAGC CAAGCCGCAC AGACCCGAGA ATTCGGAGGC
2301 CACCACACAA CACACACACA CACACATACA CACACACACA CACACAGCC
2351 AGGAGCAAGG GAGCTTTCGG GCCACACTCC CAGACGCTC CCTGAGCCCT
2401 GGAACCCGGA CTCGTGTGTC CTGGCCTTCC ATACCCCTG GCAGATCATC
2451 CTGCGGTCCC ACCCCAGATC CCCTCCTCCT CGCCATCCCA TTCTGCCCCC
2501 TCCCCACCCCT GGGTACAGAA AGGGACTGAA GTGTGGGCA GAGAGGGGGC
2551 TTAAGGCCCC TGGGCACAGG CTGGGATCAG GGCAGTGAG GAAGGGCA (SEQ ID NO:1)

```

FEATURES:

5'UTR: 1-774
 Start Codon: 775
 Stop Codon: 2046
 3'UTR: 2049

2/9

HOMOLOGOUS PROTEINS:**Top 10 BLAST Hits:**

gi 4115429 dbj BAA36362.1 (AB010154) serin/threonine protein k...	814	0.0
gi 7427988 pir S71887 serine/threonine-specific kinase (EC 2.7...	253	3e-66
gi 7302913 gb AAF57985.1 (AE003806) CG4945 gene product [Droso...	178	7e-44
gi 7297166 gb AAF52433.1 (AE003614) CG11221 gene product [Dros...	169	6e-41
gi 2499650 sp Q11090 YWY3_CAEEL PUTATIVE SERINE/THREONINE-PROTE...	165	7e-40
gi 7298323 gb AAF53551.1 (AE003652) grp gene product [alt 1] [...	132	6e-30
gi 7302570 gb AAF57652.1 (AE003798) CG15072 gene product [Dros...	131	2e-29
gi 3047011 gb AAC13566.1 (AF057041) Ser/Thr kinase [Drosophila...	130	2e-29
gi 7595800 gb AAF64455.1 AF240782_1 (AF240782) ELKL motif kinas...	129	7e-29
gi 7595802 gb AAF64456.1 AF240783_1 (AF240783) ELKL motif kinas...	129	7e-29

Tissue Expression:

Human brain
 Human Placenta
 Human Kidney
 Human Heart

3/9

```

1 MSVGCPEPEP PRSLTCCGPG TAPGPGAGVP LLTEDMQALT LRTLAASDVT
51 KHYELVRELK KGTYGKVDLV VYKGTGKMA LKFVNKSKTK LKNFLREVSI
101 TNSLSSSPFI IKVFDVVFET EDCYVFAQEY APAGDLFDII PPQVGLFEDT
151 VKRCVQQLGL ALDFMHGRQL VHRDIKPELV LLFDRECRRV KLADFGMTRR
201 VGCVRKRVSG TIPYTAPEVC QAGRADGLAV DTGVDVWAFG VLIFCVLTGN
251 FFWEAASGAD AFFEEFVRWQ RGRLPGLPSQ WRRFTEPALR MFQRLLALEP
301 ERRGPAKEVF RFLKHELTSE LRRRPSHRAR KPPGDRPPAA GPLRLEAPGP
351 LKRTVLTESG SGSRPAPPAV GSVPLPVVPV VPVPVPVPVP EPGLAPQGGP
401 GRTDGRADKS KGQVVLATAI EICV (SEQ ID NO:2)

```

FEATURES:

Functional domains and key regions:

Prosite results:

[1] PDOC00001 PS00001 ASN_GLYCOSYLATION

N-glycosylation site

85-88 NKSK

[2] PDOC00004 PS00004 CAMP_PHOSPHO_SITE

cAMP- and cGMP-dependent protein kinase phosphorylation site

Number of matches: 3

```

1 206-209 KRVS
2 282-285 RRFT
3 323-326 RRPS

```

[3] PDOC00005 PS00005 PKC_PHOSPHO_SITE

Protein kinase C phosphorylation site

Number of matches: 4

```

1 40-42 TLR
2 150-152 TVK
3 198-200 TRR
4 326-328 SHR

```

[4] PDOC00006 PS00006 CK2_PHOSPHO_SITE

Casein kinase II phosphorylation site

Number of matches: 4

```

1 215-218 TAPE
2 232-235 TGVD
3 257-260 SGAD
4 418-421 TAIE

```

[5] PDOC00008 PS00008 MYRISTYL

N-myristoylation site

76-81 GTKMAL

[6] PDOC00100 PS00108 PROTEIN_KINASE_ST

Serine/Threonine protein kinases active-site signature

170-182 LVHRDIKPEVLL

Membrane spanning structure and domains:

Helix	Begin	End	Score	Certainty
1	19	39	1.125	Certain
2	239	259	1.661	Certain
3	374	394	1.254	Certain

4/9

BLAST Alignment to Top Hit:

>gi|4115429|dbj|BAA36362.1| (AB010154) serin/threonine protein
kinase [Rattus norvegicus]
Length = 417

Score = 814 bits (2079), Expect = 0.0

Identities = 401/424 (94%), Positives = 404/424 (94%), Gaps = 7/424 (1%)

Query: 1 MSVGCPEPEPERSLTCCGPGTAPGPGAGVPLLTEDMQALTTLRTLAASDVTKHYELVRELG 60
MSVGCPEPEP SL CCGPG AP PGAGVPLLTEDMQALTTLRTLAASDVTKHYELVRELG
Sbjct: 1 MSVGCPEPEPLHSLPCCGPGAAPVPGAGVPLLTEDMQALTTLRTLAASDVTKHYELVRELG 60

Query: 61 KGTYGKVDLVVYKGTGTMALKFVNKSKTKLNFLREVSITNSLSSSPFIKVFVDVVFET 120
KGTYGKVDLV YKGTGTMALKFVNKSKTKLNFLREVSITNSLSSSPFIKVFVDVVFET
Sbjct: 61 KGTYGKVDLVAYKGTGTMALKFVNKSKTKLNFLREVSITNSLSSSPFIKVFVDVVFET 120

Query: 121 EDCYVFAQEYAPAGDLFDIIPPQVGLPEDTVKRCVQQLGLALDFMHGRQLVHRDIKPENV 180
E+CYVFAQEYAPAGDLFDIIPPQVGLPEDTVKRCVQQLGLALDFMH RQLVHRDIKPENV
Sbjct: 121 EECYVFAQEYAPAGDLFDIIPPQVGLPEDTVKRCVQQLGLALDFMHSRQLVHRDIKPENV 180

Query: 181 LLFDRECRVKLADFGMTRRVGCRVKRVSGTIPYTAPEVCQAGRADGLAVDTGVDVWAFG 240
LLFDRECRVKLADFGMTRRVGCRVKRVSGTIPYTAPEVCQAGRADG AVDTGVDVWAFG
Sbjct: 181 LLFDRECRVKLADFGMTRRVGCRVKRVSGTIPYTAPEVCQAGRADGFAVDTGVDVWAFG 240

Query: 241 VLIFCVLTGNFPWEAASGADAFEEFVRWQGRPLPGLPSQWRRFTEPALRMFORLLALEP 300
VLIFCVLTGNFPWEAASGADAFEEFVRWQGRPLPGLPSQWRRFTEPALRMFORLLALEP
Sbjct: 241 VLIFCVLTGNFPWEAASGADAFEEFVRWQGRPLPGLPSQWRRFTEPALRMFORLLALEP 300

Query: 301 ERRGPAKEVFRFLKHELTSELRRRPSHRARKPPGDRPPAAGPLRLEAPGPKRTVLTESG 360
ERRGPAKEVFRFLKHELTSELRRRPSHRARKPPGDR P GPLRLEAPGPKRTVLTESG
Sbjct: 301 ERRGPAKEVFRFLKHELTSELRRRPSHRARKPPGDRLP--GPLRLEAPGPKRTVLTESG 358

Query: 361 SGRSPAPPAVGSVPLPVPVFPVVPVPEPGLAPQGPGRDGRADKSKGQVVLATAI 420
SGSRP+PP+VG V VVPVFPVVPVPE GLAP PPGRTDGRADKSKGQVVLATAI
Sbjct: 359 SGRSPSPSVGPV-----VPVFPVFPVPEAGLAPPAPPGRTDGRADKSKGQVVLATAI 413

Query: 421 EICV 424
EICV
Sbjct: 414 EICV 417 (SEQ ID NO:4)

Hammer search results (Pfam):

Scores for sequence family classification (score includes all domains):

Model	Description	Score	E-value	N
PF00069	Eukaryotic protein kinase domain	196.8	3.4e-55	1
CE00022	CE00022 MAGUK_subfamily_d	10.4	0.0057	1
CE00031	CE00031 VEGFR	3.7	0.3	1
CE00292	CE00292 PTK_membrane_span	-63.6	2.7e-05	1
CE00287	CE00287 PTK_Eph_orphan_receptor	-86.0	0.0094	1
CE00291	CE00291 PTK_fgf_receptor	-95.8	0.003	1
CE00286	E00286 PTK_EGF_receptor	-128.6	0.0035	1
CE00290	CE00290 PTK_Trk_family	-134.9	4.4e-06	1
CE00288	CE00288 PTK_Insulin_receptor	-211.9	0.018	1
CE00016	CE00016 GSK_glycogen_synthase_kinase	-260.1	0.028	1

5/9

Parsed for domains:

Model	Domain	seq-f	seq-t	hmm-f	hmm-t	score	E-value
CE00022	1/1	161	182 ..	133	154 ..	10.4	0.0057
CE00031	1/1	157	199 ..	1054	1094 ..	3.7	0.3
CE00286	1/1	53	284 ..	1	263 []	-128.6	0.0035
CE00288	1/1	55	291 ..	1	269 []	-211.9	0.018
CE00290	1/1	54	291 ..	1	282 []	-134.9	4.4e-06
CE00287	1/1	53	296 ..	1	260 []	-86.0	0.0094
PF00069	1/1	53	309 ..	1	272 []	196.8	3.4e-55
CE00292	1/1	53	313 ..	1	288 []	-63.6	2.7e-05
CE00291	1/1	53	313 ..	1	285 []	-95.8	0.003
CE00016	1/1	2	365 ..	1	433 []	-260.1	0.028

6/9

```

1 GCATGATAGG TGCAGCAAAC TACCATGGCA CACGTTTACC TATGTAACAA
51 GCCTGCACAT CCTGCACATG TACCCAGAC TAAAAATTAA AATAAATAAA
101 TAAAAATTAG CCAGGTGTGG TGGCACATGC CTGTAATCCA ATCTACTCAG
151 GAGGCTGAGA TGGGAGGATA GCTTAAGCCT GGGAGSTCGA GGCTGCAGTG
201 AGCTGTGATT GCCCACTGC ACTCCAGCCT GGGTGACAGA GCAAGACCCT
251 GTCTCAGAAA TAAAAATAAC AACAAAGCCG GAGCAGTAGC TCATGCCTGT
301 AATCCAGACA CTTTGGGAGG GCCAGGCAGA GGGATCACTT GAATCCAGGA
351 TTTGAGAGCC AGCCTGGGCC ACATAGTGGG ACCCCCTCT CTACAATCCA
401 AATAAAACCA ACGCTTCTGA ATGGGAGTAC CCGTGTGAAC TCGGTATCTG
451 GCTGTGTCTG TGTGACATAA ACAGGGGCCT TGCCTGACAC TGTGTGTGGG
501 TGGCAGCATG AGGCAGAGGG GCTGGTGCCA CCAAGCGCAG GGTCTGGCAG
551 TGA CTGGTCTG TCGGGGAGCT GACTCAAGCC TGGCCCTGA GGCTTTGGGG
601 AAGGGCAGCG GACCAAGATG CTTGTGCCCC CCTTGTGGTT ATCTTGGGCC
651 TGGCATCCGG GCCCATCCCTC AAGTTTTCTG GGTCTGGGG AGGGCAGAGG
701 GGCTGGAGGA GGGGACCCCT GCCTGATGTC ACACCTCATG CTCAACACCC
751 CTACCAACA GGGAGAAGAT GAGCGTGGGC TGCCAGAGC CTGAGCCGCC
801 CCGCTCCCTG ACCTGCTGTG GGCAGGGGAC TGCCCTGGG CCTGGTGCCG
851 GTGTGCCCT TCTCACTGAA GACATGCAGG CCCTGACTCT CCGCACACTG
901 GCCGCGAGCG ACGTCACCAA GCACTACGAA CTAGTCCGGG AGCTGGGCAA
951 AGGCACCTAT GGAAGSTTG ACCTGGTGGT CTACAAGGGC ACAGGTGAAC
1001 AAGTGCAGGG TGGCAGGGCT GAGAGGTTGG GGTGGGGCAA GGCTGGGAGG
1051 TCAGGTTTGG GGGACATGAC CTGTCAGCTG GGGCGGGGCT CTCTGGTGCT
1101 CTGTGAAGC CAGGAGGCAG GGTGAGGGC CAGATGTAGA GGATGAGGCC
1151 TGAGGCAGCC CAAGGGGAAA GAGACTGGGC AGATGGGGCA AGGGAGGAAT
1201 CCGGGGCCAG AGTGGGCCAG GGTACAGGAT GGGCTGCTGT GGGGCCATCT
1251 GGGGTGACTT TGAGACAGCC CAAGGGGCTG TGCCAGGAA GTGTCTGGGG
1301 AGGGCAGGGC TGCCGGCTGT GTCTGAGTAT CACAGCGTC TCAGGGATGT
1351 CTGGGCCAGC GAAGGTGGAT GGAGAGTGAG GGTGGTTCT CAGGAACAGG
1401 GTGCCACACT TAATGGGTGG TGAAGGACC TGTGAGGTCA ATATTGCAAT
1451 CACCATCTCT CAGGTGAGGA CAGGGAGACC TAGGCCAATT CAGCCACATA
1501 GCCAATGCCC TGCAGCTACA GAGGCTCTGA ACCAAAACGA GACCCAGGA
1551 GTCATCTCCA GAGCCTTGTG GCTTAGTCAC TGAGCTTGAT ACCTCCCCCA
1601 CACTGTAGGT CACAGCCGTG CCACCCAGCC AGCCAGGGGC TGGGCTGTG
1651 TGAGCTCCCA CAGCTGCACG CGCTTGGGTC CAGGGGCTTT GTGCTAAGTG
1701 AGGGCAGCAG GAGGAGCACC TAACATGGGG TCACCTGAGC TTTGTTACTT
1751 GCTTGCTGTG TGACCTTGAG CAAGTGACTT CACCTCTCTG TGCTTCAGAG
1801 TCCTTCTCTG TAAATAGGG TAACATTAGT GCACAACCCA TACAATCATA
1851 ATGAAGTGTG AGTTGTGAAT GTGCAGTGCT GAAGGCAGGG CCTGCGATGT
1901 GTAAATGCTC CGTGGACACA CATGTGTGCT CCACCCAGCT ATGTACCAGA
1951 TGGGCACAGA TGCTTGCCCA GGCACAGAGT TGTGGACACA TGCTTGCAG
2001 TGTCTCATTT CTTATTCATT CATCCATTTA GCAAGACAGG AAGCTTAGGG
2051 AGACCCGTTT TAGATGGGGT AGGCTGACAA GATAAATAAG CATATGGCGG
2101 GCAGGACAAA ATGAGAGAGG TGGAGGGCAT CACAGGCCCC CTGCCCCCT
2151 CCTCTTGAG AGCTGCAGAG TGGGTGTAGA AGGCTCAGGT TGACCTGCC
2201 TGCACTGGCT TGGGCAAGTC CTTTCCCTCT TCTGGGTCTG TTTCCATCCG
2251 TGAGATGAGG ACAGTCATGC CTGCTGGGGA CCCTGTTGCA CCAGGGTCCA
2301 GAGACAGGCA TGGGTGCATC CAGTGCAGAG GCACTGGGAG AGGGGGCTTC
2351 AACCTGTGTT CTGTTGCTCC CATCAGGCAC AAAAATGGCA CTGAAGTTTG
2401 TGAACAAGAG CAAAACCAAG CTGAAGAACT TCCTACGGGA GGTGAGCATC
2451 ACCAACAGCC TCTCCTCCAG CCCCTTCATC ATCAAGGTCT TTGACGTGGT
2501 CTTTGAGACA GAGGACTGCT ACGTCTTTGC CCAGGAGTAC GCACCTGCTG
2551 GGGACCTGTT TGACATCATC CCTCCCCAGG TACTCGGGAT GGTGGCATAG
2601 GGTGGGGAAA GGTCTTCAG GGTCCCAGAG TGTGAGAGTG GGAGTGGAGT
2651 CAGACCATTT AATTAACAAG TATTTACTGG GTGCCTGCTG TATGTGCGTT
2701 ACCATTTGGG GAGGTGGGGA TGTGCAGTAA GGAAGACAAA AGTCCCTGTT
2751 CTAGTGGGAA ACTGACACTC CACAGCGGGC CAGATAATAA CAGATGGAGA
2801 TGAGTGCCTA AAAGGAGACA GTGAGAATGA TGGGATGAAG TCACTGGGCC
2851 TGCCCTGGG GCTACACAAG AGGAGAGGTG TCAGATCCAC CTGGGAAGGG
2901 GCCCTCAGAG GAAGCGACCC TGAACCGGG ACGGTGGGG AGGGTTCCAG
2951 GCACTAGCTT TAAATCTGCT CTGCCACTTG CTGGCTGAGT GATGAGACCT
3001 TCGGAGCAGG TCCTCCTTCT TTGCTGAGCA CCTACTACAT GCCAGAACT
3051 GGAGACACAG ATGCACGGAC ACAGCAGGGA ACAGGACGGG AAGCTCAGGG
3101 AGCCCGTTT TAGTTGGGGA AGACCGACGA GATAAGTATC TAGCAGGCAG
3151 GGC AAAATGA CAGCAGGTGG AGGGCGCCGC GGACCCCTC ATCAACCTCC
3201 TGGAGAGCG CGTGTCCCTC CTGGAGCCCC GATGTCCCA TAGGAGAAGC
3251 AGGCATGGTA GCCACTATGA GGATTGGATG AGACAGCGGG GGAAAGGGCG
3301 CTCAGCAGCA TCCGGGCCGC GTCTGCGCGG TCGCCCCAGT TACTGGGGAC

```

FIGURE 3, page 1 of 4

7/9

3351 AGGGTGGGAG GCGAAAACCG CCTTGCTAGA GAGGGAGCTG GAGGGGAGGG
 3401 CGCGCGGGCG GGCCTGGAG AGCTGGAAC AGCGCGGCTT CCCCCGGCG
 3451 CCCGCAGGTG GGGCTCCCTG AGGACACGGT GAAGCGCTGT GTGCAGCAGC
 3501 TGGGCTGGC GCTGGACTTC ATGCACGGGC GGCAGCTGGT GCACCGCGAC
 3551 ATCAAGCCCG AGAACGTGCT GCTGTTGAC CGCGAGTGCC GCCGCGTAAA
 3601 GCTGGCCGAC TTCGGCATGA CGCGCCGCGT GGGCTGCGC GTCAAGCGCG
 3651 TGAGCGGCAC CATCCCTTAC ACGGCGCCTG AGGTGTGCCA GCGGGGCGCG
 3701 GCCGACGGGC TGGCGGTGGA CACGGCGGTG GACGTGTGGG CCTTCGGCGT
 3751 GCTCATCTTC TGGGTGCTCA CCGCAACTT CCCGTGGGAG GCGGCGTCGG
 3801 GCGCCGACGC CTTCTTCGAG GAGTTCGTGC GCTGGCAGCG GGGCCGCTCG
 3851 CCGGGGCTGC CTTTCGAGTG GCGCCGCTTC ACCGAGCCCG CGCTGCGCAT
 3901 GTTCCAGCGC TTAAGTGGCC TGGAGCCCGA GCGCCGCGGC CCAGCCAAGG
 3951 AGGTGTTCCG CTTCTCAAG CACGAGCTCA CGTCCGAGCT GCGCCGCGCG
 4001 CCTTCGACAC GCGCGCGCAA GCCCCCCGGG GACCGCCCGC CCGCCGCGCG
 4051 GCCACTGCGC CTCGAGGCGC CTGGGCGGCT CAAGCGGAGC GTGCTGACCG
 4101 AGAGCGCGGC CGGCTCCCGG CCGCGCGCCC CCGCGCTCGG GTGCGTGCCC
 4151 TTGCCCCTGC CGGTGCCGGT GCCAGTGCCC GTGCCGCTGC CTGTGCCCGA
 4201 GCGCCGCTTA GCTCCCGAGG GCGCCCCCGG CCGGACCGAC GCGCGCGCGG
 4251 ACAAGAGCAA AGGGCAGGTG GTGCTGGCCA CGGCCATCGA GATCTGCGTT
 4301 TGAGTGCCTT CCGCGCCCTT CGGACCCGGG AGCAGCCCGG GCGCGCCCGG
 4351 AGCCCGGTGC CCCGGTGCAG CGGTAGGGAA TGGAGCCACC TCGCCGCGGG
 4401 GCAGGGGGCG CAGCGGTAGA CTAGGCAGGA CCGCGCCCGG CACCTGTGTC
 4451 GTCCCCGCGG GGTGCTGAG GGGGCCACCA AAGACCCCTA GCGCGGCTGC
 4501 GTGAGCGGGG GCTTGGCCCA GAGGAGCCAA GCCGCACAGA CCGAGAATT
 4551 CGGAGGCCAC CACACAACAC ACACACACAC ACATACACAC ACACACACAC
 4601 ACACGCCAGG AGCAAGGGAG CTTTCGGGCC AACTCCCGAG ACGCCTCCCT
 4651 GAGCCCTGGA ACCCGGACTC GTTGCTCCTG GCCTTCCATA CCCCTTGCA
 4701 GATCATCCTG CGGTCCCAAC CCAGATCCCC TCCTCCTCGC CATCCCATTC
 4751 TGCCCCCTCC CCACCTGGG TACAGAAAGG GACTGAAGTG TTGGGCAGAG
 4801 AGGGGGCTTA AGGCCCCTGG GCACAGGCTG GGATCAGGGC AGTGAGCGAA
 4851 GGGCAGCTGT GTCCTGCCCT CCCTTCTGGA GGTGAGGGG GAGAGGCCAA
 4901 GCCCTTGGA AATGTAGCAA ATGTCTGGAT GTCGCATAAG TGCGTGTATG
 4951 TGCGGACAGG GCCCGAGAA GCTAGTGAAT CCTGCACACC CCCATTGCAC
 5001 AATGAAATC ACAGCCAGG AGGGAGGGTA GCTTGGCACT GGCTGAGAAA
 5051 TAGAGTCTCT TCCCCGCCCC TCCCCCTAAC CACAAGGGAT TGTCTGACA
 5101 ACTTGTGGGG ATAGAAGGGC TCACAGGGCA GGGGTCTCAG CTGCCCCCAT
 5151 CCTTAGGGCA GGGGAGTTAG TGTGGAGCCG AGAGCAGGTC CCAGTCCCCC
 5201 CTGCCAGCCG CACTGTCCCA GGCCGAGGGA CCTCTGCCG GTCTCTCCAG
 5251 CCCTTGCCAC ACAGCCTAGA CGTAGTAGCC TGGGCTTCCA GCAGGTGGCG
 5301 AGCTGTGTCG TGCTGGAAT TCTCTCTGGG TTTCTTGGG TCAAACATGC
 5351 CAACCTCCAA GACCCATCC TCACGTCTCC CACTTTCTG GCGCTGGAGT
 5401 GTGCAGGGCG TAGGACCTGC ATGTGTGGGT GTGAGAATGG GGGCGGTGGA
 5451 CACGAGGGG CGAGTGTGTG ACTAGGTGTG TGTGCACATG TGTAGGGTGC
 5501 AGACGCATGG GTGCCATCCT TTGCGTTCAG TGACTGTGCG TCAGACCCCC
 5551 TCACGAGCGG CCCCCCACC ACACCTGGT CCTCCAGGC AGCTGTCCCA
 5601 GGGCGCCAG GCCTGCCTTG CACCACAGCC CTCAGGAAT CCGGCAAGGA
 5651 GGCCCCGTGA GGTGGTTCA GGCCCCAGG TAGCAAAACA GAGACAACAG
 5701 CAGCCCCGCC TGACCCCTG CCCCTCTCTG TGGAGGCCCG GGACCCCCCG
 5751 AATAAGCACC ACATGGGTGA GGCTGTCCCT GTCAGGGTCC CTTGCCAGGG
 5801 TCCCTCTGG GGTCTGGGC CATTTGAGGG GCTCTTTGAT GGGCCAGGCC
 5851 GGCCAGAGTG AACTCCGAGC ACTTCTGGC TGGTGCCCA ACCTCTCCAC
 5901 TCCCCACTCA TTCCCACTT GAAAAAGGGC TATAGGTCCC CTGCCCTGCC
 5951 CGGGTCCAGT TTACAAACAG TGTGGGTGG CCGCAGGGC TGGCCCCACT
 6001 CTCCCTGCTG TGCCCACTCC TCTCCAGACT CCACCTCCCC AGTGGGTATG
 6051 GGCCCTCCAC ATGCCAGGTA AGTAGCAAAC CCCCCTCCC TCCAAGGACC
 6101 AGGTCTCAGA GAAGGCCCTG GTCAGTCCCC CCGGCCACC TGGAGCCCAT
 6151 CGGGGTGCC TCTCCAGCC GCGACTTCTC CTTTGGCTT AGGCTCGCG
 6201 ACATCCTGAT CTCTCTGCA ATAAGTAGGA ATCGAGATTC CACAGTAGAC
 6251 GTCCCTTGCC GTGCTCGCTC TCTCTCTGCG GCGCTCTCTC TCTCTCTCTC
 6301 TCTCTCTCTC TCTCTCTCTC TCTCTCTCTC CTCTTCTCT CTCTCCCTCT
 6351 CTCTGTAAAG ATCCTGTTTC GGAGTTTCCC CAGCGGTTGT AGTATCTAGT
 6401 ATGTTAGAGT TGGGAGGGGA CCATAGTTAT GTAGCCAGC CCCCTCATTC
 6451 CCAGAGGCAC CCAGAGGGCC AGCCTCCAGC CTGACCCAG AGCAGAACCG
 6501 GAACACGAGG TTGGGGCCCT GGTGCTGCCA CCTCTCTGC TGGTCGGGCT
 6551 GGGACCCCTT GCCCCTTAGG AGAGGTGTTG GTCACAGATG TTTACCTCAG
 6601 TTTATGTCAC TGTCGAAGAA CAAAAAATA ATAGCAAAAA ATAACACTGT
 6651 AGACATGAAG ACTTAGAAGA CAAAAAATA AAAATCACAC AAAAAATCTC

FIGURE 3, page 2 of 4

8/9

6701 CCTTGTGTGC ATTCTTCTGT GAAGGTACAG TGTGTATGTG TGTATGTGTG
 6751 TATGTGTGTG CGTGTCTCTG TCCCAGACCC TGTGTCCCC ACCTGCCCC
 6801 CTGTCTCTCG GTGCTTCCCA GAGACCCCTC TGAGCTGGCC TGTGGGGCAC
 6851 GGGAAGCCCC CTGGATGGGA GCGGGGGCCA CAGGTCGGCT AGAGGGTCTC
 6901 CACCAGGCCC ACTGAACAGA ACCCCACGGC TGCCAGAATG TTCCCTGAGC
 6951 CCACACTGTG GCCAGTGGGA CAGTCCTGGT GGCTGACATC AGCGTCCATG
 7001 CTTGGCTCAG GGCCTGGGGC GGGGTCTTGG GTAGAGTCCT AGCCCCAGAG
 7051 CCCCAGCCCC TCATGTCTTG CCGCCCTTCC TCCATGTGTT TGTAAATACT
 7101 CTGGCATCCT TTGGCCCTGA GAAGGTTTTT AAATGTGTTA TTTACTTCTC
 7151 TAAACATGAC GATTGCTATA AAAATAAACA AAAGTTTAGA AAAATGACCA
 7201 CTGGGTGGCT GTCTTTTCTC AAGTTTGGGG TGGAGAGGGC GGTGGGGGTG
 7251 GGGGCACACA GGTACTCTAG AACTGAAAA CTTGGGCTGG GCGGAGCGGC
 7301 T (SEQ ID NO:3)

FEATURES:

Start: 769
 Exon: 769-994
 Intron: 995-2376
 Exon: 2377-2579
 Intron: 2580-3457
 Exon: 3458-4300
 Stop: 4301

ALLELIC VARIANTS (SNPs):

Position	Major	Minor	Domain
395	A	T	Beyond ORF(5')
282	A	T	Beyond ORF(5')
2697	G	A	Intron
5406	G	C	Beyond ORF(3')
6309	C	- T	Beyond ORF(3')
6325	-	T	Beyond ORF(3')
6326	-	C	Beyond ORF(3')

Context:**DNA****Position**

395 AATAAATAAAATTAGCCAGGTGTGGTGGCACATGCCTGTAATCCAATCTACTCAGGAGG
 CTGAGATGGGAGGATAGCTTAAGCCTGGGAGGTGCGAGGCTGCAGTGAGCTGTGATTGCGC
 CACTGCACTCCAGCCTGGGTGACAGAGCAAGACCCTGTCTCAGAAATAAAATAACAACA
 AGCCGGGAGCAGTAGCTCATGCTGTAATCCAGCACTTTGGGAGGGCCAGGCAGAGGGA
 TCACTTGAATCCAGGATTTGAGACCAGCCTGGGCCACATAGTGGGACCCCTCTCTAC
 [A,T]
 ATCCAAATAAAACCAACGCTTCTGAATGGGAGTACCGTGTGAACCTCGGTATCTGGCTGT
 GTCTGTGTGACATAAACAGGGGCCCTTGCTGACACTGTGTGTGGGTGGCAGCATGAGGCA
 GAGGGGCTGGTGCCACCAAGCGCAGGGTCTGGCAGTGACTGGTCTTCGGGGAGCTGACTC
 AAGCCTGGCCCTGAGGCTTTGGGAAGGCGACGCGACCAAGATGCTTGTGCGCCCTTG
 TGGTTATCTTGGGCTGGCATCCGGGCCATCCTCAAGTTTCTGGGTTCTGGGGAGGGC

 282 TGGGAGGTGCGAGGCTGCACTGAGCTGTGATTGCGCCACTGCACTCCAGCCTGGGTGACAG
 AGCAAGACCCCTGTCTCAGAAATAAAATAACAACAAGCCGGG
 [A,T]
 GCAGTAGCTCATGCCCTGTAATCCAGCACTTTGGGAGGGCCAGGCAGAGGGATCACTTGA
 ATCCAGGATTTGAGACCAGCCTGGGCCACATAGTGGGACCCCTCTCTACAATCCAAA
 TAAACCAACGCTTCTGAATGGGAGTACCCGTGTGAACCTCGGTATCTGGCTGTGTCTGTG
 TGACATAAACAGGGGCCCTTGCTGACACTGTGTGTGGGTGGCAGCATGAGGCAGAGGGGC
 TGGTGCCACCAAGCGCAGGGTCTGGCAGTGACTGGTCTTCGGGGAGCTGACTCAAGCCTG

 2697 TTTGTGAACAAGAGCAAAACCAAGCTGAAGAAGTTCTTACGGGAGGTGAGCATCACCAAC
 AGCCTCTCTCCAGCCCTTCATCATCAAGGTCTTTGACGTGGTCTTTGAGACAGAGGAC
 TGCTACGTCTTTGCCAGGAGTACGCACCTGCTGGGGACCTGTTGACATCATCCCTCCC
 CAGGTACTCGGGATGGTGGCATAGGGTGGGGAAGGGTCTTCAGGGTCCAGAGTGTGAG
 AGTGGGAGTGGAGTCAAGACATTTAATTAACAAGTATTTACTGGGTGCTGTGTATGTC
 [G,A]

FIGURE 3, page 3 of 4

GTTACCATTTGGGGAGGTGGGGATGTGCAGTAAGGAAGACAAAAGTCCCTGTTCTAGTGGG
GAAACTGACACTCCACAGCGGGCCAGATAATAACAGATGGAGATGAGTGCCCTAAAAGGAG
ACAGTGGAGAATGATGGGATGAAGTCACTGGGCCGTCCCTCGGGCTACACAGGAGGAG
GTGTGAGATCCACCTGGGAAGGGGCCCTAGAGGAAGCGACCTGGAACCGGGACCGTGG
GGGAGGGTTCAGGCACTAGCTTTAAATCTGCTCTTGCCACTTGCTGGCTGAGTGATGAGA

6326 AGACTCCACCTCCCCAGTGGGTATGGGCCCTCCACATGCCAGGTAAGTAGCAAACCCCA
CTCCCTCCAAGGACCAAGTCTCAGAGAAGGCCCTGGTCAC TGCCCCGGCCACCTGGAG
CCCATCGGGCTGCCCTCTCCAGCCGCGACTTCTCCTTTTGCCCTTAGGCGCTCGCGACAT
CTGATCTCTCTGCAATAACTAGGAATCAGATTCCAGACTAGACGTCCCTTGCCGTGCT
CGCTCTCTCTCTCGCGCGCT
[-, C]
TCCTCTCTTTCTCTCTCTCCCTCTCTCTGTTAAGATCCTGTCGGGAGTTTCCCCAGCG
TTGTAGTATCTAGTATGTTAGAGTTGGGAGGGGACCATAGTTATGTAGCCAGCCCCCTC
ATTCCCAGAGGCACCCAGAGGGCCAGCCTCCAGCCTGACCCAGAGCAGAACCGGAACCC
CAGGTTGGGGCCCTGGTGCTGCCACCTCTCTGCTGGTGGGCTGGGACCTTTGCGCCCT
TAGGAGAGGTTGTGGTCACAGATGTTTACTCAGTTTATGTCACTGTCAAGAACAAAA

	#	SHGCNAME	CHROM#	LOD SCORE	DIST.(cRs)
	1	SHGC-10032	16	12.45	9
	2	SHGC-11302	16	12.1	13
	3	SHGC-6754	16	11.48	14
	4	SHGC-57443	16	9.08	24
	5	SHGC-295	16	7.79	33

SEQUENCE LISTING

<110> WEI, Ming-Hui et al.

<120> ISOLATED HUMAN KINASE PROTEINS, NUCLEIC
ACID MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES
THEREOF

<130> CL000536-PCT

<140> (tba)

<141> 2001-05-17

<150> US 09/816,094

<151> 2001-03-26

<150> US 09/734,032

<151> 2000-12-12

<150> US 60/205,228

<151> 2000-05-17

<160> 4

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2598

<212> DNA

<213> Human

<400> 1

```

gggagcgag cccgggagg cgcgggggccc gggggccgag cggcaggcgg agcgcgagct 60
ggagccgag cgggagccc ggccaggccc ggggcccggg ggcagggccc gggctgctcg 120
tagcggggc gaccgagccc ccagcggtct gaggggcttc cagcgcccgc cgggtggccgg 180
gaccactaa agccccgca gccgaggagt gcggggagcc ccctccaca tccaggatcc 240
ggcgagcctc ggggaagagg gggggccctc ccggatccga caccgagcga ctcccctgcg 300
gggaaagcgg agacttcctc ggtatttaga agacagcaag cccctacgg caccgcaagg 360
actccccctc ctacgtctgg gccccgccc caagacctag aacgcagtgc cccaggccg 420
ggattgagag aacccccctc caagatccgg tcattacaac tccacacctc aagacaagaa 480
gaccagctc agaacgccc tagatcaggg gatcccaatt cccccaact ccggtacata 540
gaaatcccaa atctaggcag ccggggacag caagagacac tctcaccagc aagaagcctc 600
ggggatcccc cccctaaagc tccaggactt gggcgactga gcccctggcg gcaccgcttg 660
caccgaggtc catggtctg gcgccctgag ccccggggc cgggcagacg aagaccgca 720
cggcgcccag gccccctgcc gcggcgctcc cgcggcccca gcccagggag aagatgagcg 780
tgggctgccc agagcctgag ccgcccgcct ccctgacctg ctgtgggccc gggactgccc 840
ctgggacctg tgccggtgtg ccccttctca ctgaagacat gcaggccctg actctccgca 900
cactggccgc cagcgacgtc accaagcact acgaactagt ccgggagctg ggcaaaggca 960
cctatgggaa ggttgacctg gtggtctaca agggcacagg cacaaaaatg gcaactgaagt 1020
ttgtgaacaa gagcaaaacc aagctgaaga acttcctacg ggaggtgagc atcaccaaca 1080
gcctctcctc cagccccctc atcatcaagg tctttgacgt ggtctttgag acagaggact 1140
gctacgtctt tgcccaggag tacgcacctg ctggggacct gtttgacatc atccctccc 1200
agggtgggct ccctgaggac acggtgaagc gctgtgtgca gcagctgggc ctggcgcttg 1260
acttcatgca cggggcgag ctggtgcacc gcgacatcaa gcccgagaac gtgctgctgt 1320
tcgaccgca gtgcggccc gtaaaagctg ccgacttcgg catgacgcgc cgcgtgggct 1380
gccgctcaa gcgcgtgagc ggcaccatcc ctacacggc gcctgaggtg tgccaggcgg 1440
gccgcccga cgggctggcg gtggacacgg gcgtggacgt gtgggcttc ggcgtgctca 1500
tcttctgctg gctcaccgca aacttccgt gcggaggcgc gtcgggcgcg gacgccttct 1560
tcgaggagtt cgtgcgtgag cagcggggcc gcctgccggg gctgccttcg cagtggcgcc 1620
gcttaccga gcccgcgctg gcgatgttcc agcgttact ggccctggag cccgagcgcc 1680
gcggcccagc caaggaggtg ttccgcttcc tcaagcacga gctcactgcc gagctgcgcc 1740
gccggccctc gcaccgcgcg cgcaagcccc ccggggaccg cccgcccgcg gccggggccac 1800
tgcgccctga ggcgcctggg ccgctcaagg ggacgggtgct gaccgagagc ggcagcggtc 1860

```

```

ccccggccgc gccccccgcc gtcgggtcgg tgccttgcc cgtgccggtg ccggtgccag 1920
tgcccggtgcc ggtgcctgtg cccgagcccg gcctagctcc ccagggggccc cccggccgga 1980
ccgacggccg cgcggaacaag agcaaagggc aggtggtgct ggccacggcc atcgagatct 2040
gcgtctgagt cgcctccgcc gccctcggac ccgggagcag cccggggccc ccccgagccg 2100
gtgcccgggtg cggcggtagg gaatggagcc acctcgccgc ggggcagggg gcgcagcggg 2160
agactaggca ggacgcggcc cggcacctgg tccgtccccg gcgggctggt gagggggcca 2220
ccaaagaccc ctacgcggc ctggtgagcg ggggcttggc ccagaggagc caagccgcac 2280
agacccgaga attcggaggc caccacacaa cacacacaca cacacataca cacacacaca 2340
cacacacgcc aggagcaagg gagctttcgg gccacactcc cagacgcctc cctgagccct 2400
ggaacccgga ctcgttgctc ctggccttcc atacccctg gcagatcatc ctgcggtccc 2460
accccagatc cctctctcct cgccatccca ttctgcccc tccccaccct gggtagagaa 2520
agggactgaa gtgttgggca gagagggggc ttaaggcccc tgggcacagg ctgggatcag 2580
ggcagtgagc gaagggca                                2598

```

<210> 2

<211> 424

<212> PRT

<213> Human

<400> 2

```

Met Ser Val Gly Cys Pro Glu Pro Glu Pro Pro Arg Ser Leu Thr Cys
1          5          10          15
Cys Gly Pro Gly Thr Ala Pro Gly Pro Gly Ala Gly Val Pro Leu Leu
20          25          30
Thr Glu Asp Met Gln Ala Leu Thr Leu Arg Thr Leu Ala Ala Ser Asp
35          40          45
Val Thr Lys His Tyr Glu Leu Val Arg Glu Leu Gly Lys Gly Thr Tyr
50          55          60
Gly Lys Val Asp Leu Val Val Tyr Lys Gly Thr Gly Thr Lys Met Ala
65          70          75          80
Leu Lys Phe Val Asn Lys Ser Lys Thr Lys Leu Lys Asn Phe Leu Arg
85          90          95
Glu Val Ser Ile Thr Asn Ser Leu Ser Ser Ser Pro Phe Ile Ile Lys
100         105         110
Val Phe Asp Val Val Phe Glu Thr Glu Asp Cys Tyr Val Phe Ala Gln
115         120         125
Glu Tyr Ala Pro Ala Gly Asp Leu Phe Asp Ile Ile Pro Pro Gln Val
130         135         140
Gly Leu Pro Glu Asp Thr Val Lys Arg Cys Val Gln Gln Leu Gly Leu
145         150         155         160
Ala Leu Asp Phe Met His Gly Arg Gln Leu Val His Arg Asp Ile Lys
165         170         175
Pro Glu Asn Val Leu Leu Phe Asp Arg Glu Cys Arg Arg Val Lys Leu
180         185         190
Ala Asp Phe Gly Met Thr Arg Arg Val Gly Cys Arg Val Lys Arg Val
195         200         205
Ser Gly Thr Ile Pro Tyr Thr Ala Pro Glu Val Cys Gln Ala Gly Arg
210         215         220
Ala Asp Gly Leu Ala Val Asp Thr Gly Val Asp Val Trp Ala Phe Gly
225         230         235         240
Val Leu Ile Phe Cys Val Leu Thr Gly Asn Phe Pro Trp Glu Ala Ala
245         250         255
Ser Gly Ala Asp Ala Phe Phe Glu Glu Phe Val Arg Trp Gln Arg Gly
260         265         270
Arg Leu Pro Gly Leu Pro Ser Gln Trp Arg Arg Phe Thr Glu Pro Ala
275         280         285
Leu Arg Met Phe Gln Arg Leu Leu Ala Leu Glu Pro Glu Arg Arg Gly
290         295         300
Pro Ala Lys Glu Val Phe Arg Phe Leu Lys His Glu Leu Thr Ser Glu
305         310         315         320
Leu Arg Arg Arg Pro Ser His Arg Ala Arg Lys Pro Pro Gly Asp Arg
325         330         335

```

```

Pro Pro Ala Ala Gly Pro Leu Arg Leu Glu Ala Pro Gly Pro Leu Lys
          340          345          350
Arg Thr Val Leu Thr Glu Ser Gly Ser Gly Ser Arg Pro Ala Pro Pro
          355          360          365
Ala Val Gly Ser Val Pro Leu Pro Val Pro Val Pro Val Pro Val Pro
          370          375          380
Val Pro Val Pro Val Pro Glu Pro Gly Leu Ala Pro Gln Gly Pro Pro
          385          390          395          400
Gly Arg Thr Asp Gly Arg Ala Asp Lys Ser Lys Gly Gln Val Val Leu
          405          410          415
Ala Thr Ala Ile Glu Ile Cys Val
          420

```

<210> 3

<211> 7301

<212> DNA

<213> Human

<400> 3

```

gcatgatagg tgcagcaaac taccatggca cacgtttacc tatgtaacaa gcctgcacat 60
cctgcacatg taccacagac taaaaattaa aataaataaa taaaaattag ccagggtgtgg 120
tggcacatgc ctgtaatcca atctactcag gaggtcgaga tgggaggata gcttaagcct 180
gggagggtcga ggctgcagtg agctgtgatt ggcgcactgc actccagcct gggtgacaga 240
gcaagaccct gtctcagaaa taaaaataac aacaagccgg gagcagtagc tcatgcctgt 300
aatcccagca ctttgggagg gccaggcaga gggatcactt gaatccagga ttccgagacc 360
agcctggggc acatagtggg accccctct ctacaatcca aataaaacca acgcttctga 420
atgggagtag ccgtgtgaac tcggtatctg gctgtgtctg tgtgacataa acaggggcct 480
tgcttgacac tgtgtgtggg tggcagcatg aggcagaggg gctgtgtgca ccaagcgag 540
ggtctggcag tgactggtct tcggggagct gactcaagcc tggccctga ggctttggg 600
aaggcgagcg gaccaagatg cttgtcgccc ccttgtggtt atcttgggcc tggcatccgg 660
gcccacctc aggttttctg ggttctgggg agggcagagg ggctggagga ggggaccctt 720
gcctgatgtc acacttcatg ctcaccaccc ctacccaaca gggagaagat gagcgtgggc 780
tgcccagagc ctgagccgcc ccgtccctg acctgctgtg ggccggggac tgcccctggg 840
cctggtgccg gtgtgcccct tctcactgaa gacatgcagg cctgactct ccgcacactg 900
gccgccagcg acgtcaccaa gcactacgaa ctagtccggg agctgggcaa aggcacctat 960
gggaagggtt acctggtggt ctacaagggc acaggtgaac aagtgcaggg tggcagggct 1020
gagagggttg ggtggggcaa ggctgggagg tcagggttg gggacatgac cttgcagctg 1080
ggccgggggt ctctggtgct ctgtggaagc caggaggcag ggtcaggggc cagatgtaga 1140
gcatgaggcc tgaggcagcc caaggggaaa gagactgggc agatggggca agggaggaat 1200
ccggggccag agtggggccag ggtacaggat gggtgtgtgt ggggccatct ggggtgactt 1260
tgagacagcc caaggggctg tgcccaggaa gtgtctgggg agggcagggc tgccggctgt 1320
gtctgagtag caccagctc tcagggtgt ctggcccag gaagggtgat ggagagtga 1380
ggtggttctt caggaacagg gtgccacact taatgggttg tggaggacc tgtgaggtca 1440
atattgcaat caccatctct caggtgagga caggagacc taggccaatt cagccacata 1500
gccaatgccc tgcagctaca gaggtgtga accaaaacga gacccagga gtcatctcca 1560
gagccttgtc gcttagtcac tgagcttgat acctccccca cactgtaggt cacagccgtg 1620
ccaccagccc agccaggggc tggggctgtg tgagctccca cagctgcacg cgcttgggtc 1680
caggggcttt gtgctaactg agggcagcag gaggagcacc taacatgggg tcacctgagc 1740
tttgttactt gcttgctgtg tgaccttgag caagtgactt cacctctctg tgcttcagag 1800
tccttctctg taaaataggg taacattagt gcacaacca tacaatcata atgaagtgtg 1860
agttgtgaat gtgcagtgtc gaaggcaggg cctgcgatgt gtaaatgctc cgtggacaca 1920
catgtgtgct ccaccagct atgtaccaga tgggcacaga tgcttgccca ggcacagagt 1980
tgtggacaca tgccctgcag tgtctcattt cttattcatt catccattta gcaagacagg 2040
aagcttaggg agacccttc tagatggggg aggtgacaa gataaataag catatggcgg 2100
gcaggacaaa atgagagagg tggaggcat cacaggcccc ctgcgccct cctcttgagg 2160
agctgcagag tgggtgtaga aggtcagggt tgacctgcc tgcattggcct tgggcaagtc 2220
ctttcctctc tctgggtctg ttcccatccg tgagatgagg acagtcagtc ctgctgggga 2280
ccctgttgca ccagggtcca gagacaggca tgggtgcatc cagtgcggag gcactgggag 2340
agggggcttc aacctgttg ctgttctcc catcaggcac aaaaatggca ctgaagtttg 2400
tgaacaagag caaaaccaag ctgaagaact tcctacggga ggtgagcatc accaacagcc 2460
tctcctccag ccccttcac atcaaggctc ttgacgtggt ctttgagaca gaggactgct 2520
acgtctttgc ccaggagtac gcacctgctg gggacctgtt tgacatcatc cctccccagg 2580

```

tactcgggat	ggtggcatag	ggtggggaaa	gggtcttcag	ggtcccagag	tgtgagagt	2640
ggagtggagt	cagaccattt	aattaacaag	tatttactgg	gtgcctgctg	tatgtcgggt	2700
accatttggg	gaggtgggga	tgtgcagtaa	ggaagacaaa	agtccctggt	ctagtgggaa	2760
actgacactc	cacagcgggc	cagataataa	cagatggaga	tgagtgccta	aaaggagaca	2820
gtgagaatga	tgggatgaag	tactggggcc	gtcccctggg	gctacacaag	aggagaggtg	2880
tcagatccac	ctgggaaggg	gccctcagag	gaagcgaccc	tggaaaccggg	acggtggggg	2940
aggggttcag	gcactagctt	taaatctgct	ctgccacttg	ctggctgagt	gatgagacct	3000
tcgggagcag	tcctccttct	ttgtctgagca	cctactacat	gccagaatct	ggagacacag	3060
atgcacggac	acagcaggga	acaggacggg	aagctcaggg	agccccgttc	tagttgggga	3120
agaccgacga	gataagtatc	tagcaggcag	ggcaaaatga	cagcaggttg	agggcgccgc	3180
ggacccccctc	atcaacctcc	tggagagccg	cgtgtccctc	ctggagcccc	gatgtcccca	3240
taggagaagc	aggcatggta	gccactatga	ggattggatg	agacagcggg	ggaaagggcg	3300
ctcagcagca	tcggggccgc	gtctgcgcgg	tcgccccagt	tactggggac	aggggtgggag	3360
gcgaaaaccg	ccttgctaga	gagggagctg	gaggggaggg	cggcgggggc	ggcgctggag	3420
agctggaaac	agcgcggctt	cccccgccg	ccgcaggtg	gggtccctg	aggacacggt	3480
gaagcgctgt	gtgcagcagc	tgggcctggc	gctggacttc	atgcacgggc	ggcagctggt	3540
gcaccgcgac	atcaagcccc	agaacgtgct	gctgttcgac	cgcgagtgcc	gccgcgtaaa	3600
gctggccgac	ttcggcatga	cgcgcgcgct	gggctgccgc	gtcaagcgcg	tgagcggcac	3660
catcccttac	acggcgccctg	aggtgtgccca	ggcgggccgc	gccagcgggc	tggcggtgga	3720
cacgggctgt	gacgtgtggg	ccttcggcgt	gctcatcttc	tgcgtgctca	ccggcaactt	3780
cccgtgggag	gcggcgctcg	gcgcgcgacgc	cttcttcgag	gagttcgtgc	gctggcagcg	3840
gggcccgcctg	ccggggctgc	cttcgcagtg	gcgcgccttc	accgagcccc	cgtgcgcgat	3900
gttccagcgc	ttactggccc	tggagcccga	gcgcgcgggc	ccagccaagg	aggtgttccg	3960
cttccctcaag	cacgagctca	cgtccgagct	gcgcgcggcg	ccctcgcacc	gcgcgcgcaa	4020
gccccccggg	gaccgcccgc	ccgcgcggcg	gccactgcgc	ctcagaggcg	ctggggcgct	4080
caagcggagc	gtgctgaccg	agagcggcag	cggctcccgg	cccgcgcccc	ccgcgcctcg	4140
gtcgggtgcc	ttgcccgctg	cggtgccggt	gccagtgcgc	gtgccggtgc	ctgtgcccgca	4200
gccccggcta	gctccccagg	ggcccccccg	ccggaccgac	ggccgcgcgg	acaagagcaa	4260
agggcaggtg	gtgctggcca	cggccatcga	gatctgcgtt	tgagtgcctt	ccgcccgcct	4320
cggaccggg	agcagcccgg	gcccccccg	agcccgtgct	cccgtgcgg	cggtagggaa	4380
tggagccacc	tcgcccgggg	gcagggggcg	cagcggtaga	ctaggcagga	cgcggcccg	4440
cacctgggac	gtcccggcg	ggctggtag	ggggccacca	aagacccta	gcgcggcctg	4500
gtgagcgggg	gcttgcccca	gaggagccaa	gccgcacaga	cccagagaatt	cggaggccac	4560
cacacaacac	acacacacac	acatacacac	acacacacac	acacgccagg	agcaagggag	4620
ctttcggggc	acactcccag	acgcctccct	gagccctgga	acccggactc	gttgctcctg	4680
gccttccata	ccccctggga	gatcatcctg	cggctcccacc	ccagatcccc	tcctcctcgc	4740
catcccattc	tgcctccctc	caccctggg	tacagaaaag	gactgaagtg	ttgggcagag	4800
agggggctta	aggcccttg	gcacaggctg	ggatcagggc	agttagcgaa	gggcagctgt	4860
gtcctgccct	cccttctgga	ggctggagg	gagaggccaa	gcccttgga	aatgtagcaa	4920
atgtctggat	gtcgcataag	tgcgtgtatg	tgccggacag	gccccgagaa	gctagtact	4980
cctgcacacc	cccattgcac	aaatgaaatc	acagcccagg	agggagggtg	gcttggcact	5040
ggttgagaaa	tagagctctc	tccccgcctc	tcccctaac	cacaagggat	tgtcctgaca	5100
acttgtgggg	atagaagggc	tcacagggca	ggggtctcag	ctgcccccat	ccttagggca	5160
ggggagttag	tgtggagccg	agagcaggtc	ccagctcccc	ctgccagccg	cactgtccca	5220
ggcccaggga	cctctgcgcg	gtcctcccag	cccttgccac	acagcctaga	cgtagttagc	5280
tgggcttcca	gcaggtggcg	agctggttcg	tgtggaaat	ttctcctggg	tttcttgggg	5340
tcaaacatgc	caacctcaa	gaccccatcc	tcacgtctcc	cacttttctg	gcgctggagt	5400
gtgcagggct	taggacctgc	atgtgtgggt	gtgagaatgg	gggcggtgga	caccagggg	5460
cgagtgtgtg	actaggtgtg	tgtgcacatg	tgtagggtgc	agacgcgatg	gtgccatcct	5520
ttgcgttcag	tgactgtgcg	tccagacccc	tcaccagcgg	cccccccacc	acaccctggt	5580
cctcccaggc	agctgtccca	ggcgccccag	gcctgccttg	caccacagcc	ctcaggaaat	5640
ccggcaagga	ggccccctga	ggttggttca	ggcccccagg	tagcaaaaca	gagacaacag	5700
cagccccccg	tgacccccctg	ccctctctctg	tggaggcccg	ggacccccgc	aataagcacc	5760
acatgggtga	ggctgtccct	gtcagggtcc	cctgcagggg	tcctcctg	ggttctgggc	5820
catttgagg	gctctttgat	gggcccaggc	ggccagagt	aactccgagc	actttctggc	5880
tggtgcccga	acctctccac	tcccactca	ttcccacctt	gaaaaagggc	tataggtccc	5940
ctgccctgcc	cgggtccagt	ttacaaacag	tgtgggggtg	ccccagggcc	tggccccact	6000
ctccctgctg	tgccactcc	tctccagact	ccaactcccc	agtgggtatg	ggccctccac	6060
atgccaggga	agtagcaaac	ccccactccc	tccaaggacc	aggtctcaga	gaaggccctg	6120
gtcaactgccc	ccggcccacc	tggagcccat	cggggctgcc	tctcccagcc	gcgacttctc	6180
cttttgccct	aggcctcgcg	acatcctgat	ctctcctgca	ataactagga	atcgagattc	6240
cacagtagac	gtcccttgcc	gtgctcgtct	tctctctctc	gcgctctctc	tctctctctc	6300
tctctctctc	tctctctctc	tctctctctc	ctctttctct	ctctccctct	ctctgttaag	6360

```

atcctgttcg ggagtttccc cagccgttgt agtatctagt atgttagagt tgggagggga 6420
ccatagttat gtagcccagc cccctcattc ccagaggcac ccagagggcc agcctccagc 6480
ctgaccccag agcagaaccg gaacaccagg ttggggccct ggtgctgcca cctcctctgc 6540
tggtcgggct gggacccttt gcccttagg agagggtgtg gtcacagatg tttacctcag 6600
tttatgtcac tgtcgaagaa acaaaaaata atagcaaaaa ataactgt agacatgaag 6660
acttagaaga caaaaaaaa aaaatcacac aaaaaatctc ccttggtgcg attcttctgt 6720
gaaggtacag tgtgtatgtg tgtatgtgtg tatgtgtgtg cgtgtctctg tcccagaccc 6780
tgtgtccccc aactgcccc ctgtccttcg gtgcttccca gagaccctc tgagctggcc 6840
tgtggggcac gggaagcccc ctggatggga ggcggggcca caggtcggct agagggtctc 6900
caccaggccc actgaacaga accccacggc tgccagaatg ttccctgagc ccacactgtg 6960
gccagtggga cagtcctggt ggctgacatc agcgtccatg cttggctcag ggcctggggc 7020
ggggtcctgg gtagagtccct agccccagag ccccagcccc tcatgtcttg ccgcccttcc 7080
tccatgtgtt tgtaaatact ctggcatcct ttggccctga gaaggttttt aaatgtgtta 7140
tttacttctc taacatgac gattgtcata aaaataaaca aaagtttaga aaaatgacca 7200
ctgggtggct gtcttttctc aagtttgggg tggagagggc ggtgggggtg ggggcacaca 7260
ggtactctag aaactgaaaa cttgggctgg gcggagcggc t 7301

```

<210> 4

<211> 417

<212> PRT

<213> Rattus norvegicus

<400> 4

```

Met Ser Val Gly Cys Pro Glu Pro Glu Pro Leu His Ser Leu Pro Cys
1          5          10          15
Cys Gly Pro Gly Ala Ala Pro Val Pro Gly Ala Gly Val Pro Leu Leu
20          25          30
Thr Glu Asp Met Gln Ala Leu Thr Leu Arg Thr Leu Ala Ala Ser Asp
35          40          45
Val Thr Lys His Tyr Glu Leu Val Arg Glu Leu Gly Lys Gly Thr Tyr
50          55          60
Gly Lys Val Asp Leu Val Ala Tyr Lys Gly Thr Gly Thr Lys Met Ala
65          70          75          80
Leu Lys Phe Val Asn Lys Ser Lys Thr Lys Leu Lys Asn Phe Leu Arg
85          90          95
Glu Val Ser Ile Thr Asn Ser Leu Ser Ser Ser Pro Phe Ile Ile Lys
100         105         110
Val Phe Asp Val Val Phe Glu Thr Glu Glu Cys Tyr Val Phe Ala Gln
115         120         125
Glu Tyr Ala Pro Ala Gly Asp Leu Phe Asp Ile Ile Pro Pro Gln Val
130         135         140
Gly Leu Pro Glu Asp Thr Val Lys Arg Cys Val Gln Gln Leu Gly Leu
145         150         155         160
Ala Leu Asp Phe Met His Ser Arg Gln Leu Val His Arg Asp Ile Lys
165         170         175
Pro Glu Asn Val Leu Leu Phe Asp Arg Glu Cys Arg Arg Val Lys Leu
180         185         190
Ala Asp Phe Gly Met Thr Arg Arg Val Gly Cys Arg Val Lys Arg Val
195         200         205
Ser Gly Thr Ile Pro Tyr Thr Ala Pro Glu Val Cys Gln Ala Gly Arg
210         215         220
Ala Asp Gly Phe Ala Val Asp Thr Gly Val Asp Val Trp Ala Phe Gly
225         230         235         240
Val Leu Ile Phe Cys Val Leu Thr Gly Asn Phe Pro Trp Glu Ala Ala
245         250         255
Ser Gly Ala Asp Ala Phe Phe Glu Glu Phe Val Arg Trp Gln Arg Gly
260         265         270
Arg Leu Pro Gly Leu Pro Ser Gln Trp Arg Arg Phe Thr Glu Pro Ala
275         280         285
Leu Arg Met Phe Gln Arg Leu Leu Ala Leu Glu Pro Glu Arg Arg Gly
290         295         300

```



```

Pro Ala Lys Glu Val Phe Arg Phe Leu Lys His Glu Leu Thr Ser Glu
305                      310                      315                      320
Leu Arg Arg Arg Pro Ser His Arg Ala Arg Lys Pro Pro Gly Asp Arg
                      325                      330                      335
Leu Pro Gly Pro Leu Arg Leu Glu Ala Pro Gly Pro Leu Lys Arg Thr
                      340                      345                      350
Val Leu Thr Glu Ser Gly Ser Gly Ser Arg Pro Ser Pro Pro Ser Val
                      355                      360                      365
Gly Pro Val Val Pro Val Pro Val Pro Val Pro Val Pro Val Pro Glu
                      370                      375                      380
Ala Gly Leu Ala Pro Pro Ala Pro Pro Gly Arg Thr Asp Gly Arg Ala
385                      390                      395                      400
Asp Lys Ser Lys Gly Gln Val Val Leu Ala Thr Ala Ile Glu Ile Cys
                      405                      410                      415
Val

```

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 November 2001 (22.11.2001)

PCT

(10) International Publication Number
WO 01/088148 A3

(51) International Patent Classification⁷: **C12N 15/54**,
9/12, C12Q 1/68, C07K 16/40, A01K 67/027, A61K
38/00, G01N 33/50

20850 (US). **BEASLEY, Ellen, M.**; Celera, 45 West Gude
Drive, Rockville, MD 20850 (US).

(21) International Application Number: PCT/US01/15776

(74) Agent: **MILLMAN, Robert, A.**; Celera Genomics Corp.,
45 West Gude Drive C2-4, Rockville, MD 20850 (US).

(22) International Filing Date: 17 May 2001 (17.05.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/205,228	17 May 2000 (17.05.2000)	US
09/734,032	12 December 2000 (12.12.2000)	US
09/816,094	26 March 2001 (26.03.2001)	US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: **APPLERA CORPORATION** [US/US];
Robert A. Millman, Assistant Secretary, 761 Main Avenue,
Norwalk, CT 06859 (US).

Published:

— with international search report

(72) Inventors: **WEI, Ming-Hui**; Celera, 45 West
Gude Drive, Rockville, MD 20850 (US). **CHAN-
DRAMOULISWARA, Ishwar**; Celera, 45 West Gude
Drive, Rockville, MD 20850 (US). **YE, Jane**; Cel-
era, 45 West Gude Drive, Rockville, MD 20850 (US).
KETCHUM, Karen, A.; c/o Celera, 45 West Gude
Drive, Rockville, MD 20850 (US). **DI FRANCESCO,
Valentina**; Celera, 45 West Gude Drive, Rockville, MD

(88) Date of publication of the international search report:
16 October 2003

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN KINASE PRO-
TEINS, AND USES THEREOF

(57) Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the kinase peptides, and methods of identifying modulators of the kinase peptides.

WO 01/088148 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/15776

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/54 C12N9/12 C12Q1/68 C07K16/40 A01K67/027
A61K38/00 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 200022 Derwent Publications Ltd., London, GB; Class B04, AN 2000-249682 XP002217123 -& JP 2000 060571 A (MITSUBISHI CHEM CORP) , 29 February 2000 (2000-02-29) abstract SEQ IDs 1 and 2	1-5, 8-16, 19-22
X	--- DATABASE EMBL 'Online! 8 January 1999 (1999-01-08) Database accession no. AB010154 XP002217121 abstract --- -/--	1,2,4,5, 20-23

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

17 October 2002

Date of mailing of the international search report

31/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Andres, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/15776

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EM_HUM 'Online! EMBL; Homo sapiens chromosome 16 clone CTD-2597E15, 23 March 2000 (2000-03-23) Database accession no. AC026454 XP002217122 nucleotides 31465-38753 ---	4, 5, 22, 23
E	WO 01 38503 A (PLOWMAN GREGORY D ;CLARY DOUGLAS (US); SUGEN INC (US); WHYTE DAVID) 31 May 2001 (2001-05-31) SEQ IDs 44 and 101 abstract; claims ---	1-16, 19-23
E	WO 02 10401 A (KAPELLER LIBERMANN ROSANA ;SILOS SANTIAGO IMMACULADA (US); MEYERS) 7 February 2002 (2002-02-07) SEQ IDs 1-3 (kinase '32374') abstract; claims ---	1-16, 19-23
E	WO 02 18557 A (INCYTE GENOMICS, INC.) 7 March 2002 (2002-03-07) SEQ IDs 1 and 25 (PKIN-1) abstract; claims ---	1-16, 19-23
E	WO 02 46428 A (LEXICON GENETICS INC) 13 June 2002 (2002-06-13) the whole document -----	1-16, 19-23

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/15776

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 17-18
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 17-18

Present claims 17 and 18 relate to agents defined by reference to a desirable characteristic or property, namely their capacity to bind to a peptide derived from SEQ ID 2.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for NONE of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search impossible. Consequently, no search has been carried out for claims 17 and 18.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/15776

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
JP 2000060571	A	29-02-2000	NONE	
WO 0138503	A	31-05-2001	AU 1926001 A EP 1240194 A2 WO 0138503 A2	04-06-2001 18-09-2002 31-05-2001
WO 0210401	A	07-02-2002	AU 7904601 A WO 0210401 A2 US 2002061573 A1	13-02-2002 07-02-2002 23-05-2002
WO 0218557	A		NONE	
WO 0246428	A	13-06-2002	AU 3089202 A WO 0246428 A2 US 2002123621 A1	18-06-2002 13-06-2002 05-09-2002